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1. Introduction 
Coronary Heart Disease is major cause of morbidity and mortality among the 
cardiovascular diseases. There is an increase in Acute Coronary Syndrome due to 
raise in risk factors, unhealthy diet and lifestyle changes. Non STEMI, STEMI and 
UA constitute ACS. There is a rise in patients admitted in general medical wards with 
NSTEMI as compared to STEMI in our hospital. The reason for it is that majority of 
STEMI require intervention and hence are managed by Cardiologists. There is a 
paucity of data on morbidity and mortality – in hospital and long term, in proven cases 
of acute coronary syndrome admitted to general medical wards. This study was done 
to assess the mortality at discharge, one-month and six-month in individuals who were 
admitted with Acute Coronary Syndrome in general medical wards.  
 
2. Aim 
The aim was to study the Clinical presentation, Risk factors, Mortality - in hospital, 
one month and six months of patients admitted in general medical wards with Acute 
Coronary Syndrome. 
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3. Objective 
3.1 Primary objective 
3.1.1 All-cause mortality: in hospital, one month and six months of hospital admission 
of patients admitted with Acute Coronary Syndrome in a general medical ward. 
3.2 Secondary objectives 
3.2.1 To study the risk factors affecting the morbidity and mortality of patients 
admitted with Acute Coronary Syndrome in a general medical ward. 
3.2.2 To assess the association between socioeconomic strata and mortality from acute 
coronary syndromes. 
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4. Review of Literature 
4.1 Definition of disease 
 
According to the third universal definition as defined by the European Society of 
Cardiology / American College of Cardiology / American Heart Association / World 
Heart Federation, in 2012, any one of the following criteria meets the diagnosis of 
acute coronary syndrome (1):  
• Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac 
troponin [cTn] with at least one value above the 99thpercentile upper reference 
limit [URL]) and with at least one of the following: 
o  Symptoms of ischemia 
o  Development of pathologic Q waves in the electrocardiogram (ECG) 
o  New or presumed new significant ST-segment-T wave (ST-T) changes 
or new left bundle branch block (LBBB). 
o  Identification of an intracoronary thrombus by angiography or autopsy 
o  Imaging evidence of new loss of viable myocardium or a new regional 
wall motion abnormality. 
• ST ELEVATION MYOCARDIAL INFARCTION:  
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It is a clinical syndrome associated with characteristic symptoms of myocardial 
ischemia in association with persistent electrocardiographic (ECG) ST elevation and 
subsequent release of biomarkers of myocardial necrosis. 
o New ST elevation at the J point in at least 2 contiguous leads of 2 mm (0.2 mV) 
in men or 1.5 mm (0.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1 
mV) in other contiguous chest leads or the limb leads. 
• NON- ST ELEVATION MYOCARDIAL INFARCTION:  
It is defined as ST depressions and/or T wave inversions without ST segment 
elevations or pathologic Q waves.  
o New horizontal or down-sloping ST depression ≥0.05 mV in two contiguous 
leads and/or T inversion ≥0.1 mV in two contiguous leads with prominent R 
wave or R/S ratio >1. 
• UNSTABLE ANGINA: 
o It is defined as ischemic symptoms suggestive of an acute coronary syndrome 
without elevation in biomarkers with or without ECG changes indicative of 
ischemia.  
4.2 Cardiovascular diseases 
4.2.1 Global epidemiology 
 
According to the WHO an estimated 17.7 million people died from CVDs in 2015, 
which represents 31% of all global deaths. Among these deaths, an estimated 7.4 
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million deaths were due to coronary heart disease and 6.7 million deaths were due to 
stroke. Low and middle-income countries accounted for three quarters of these deaths. 
Among the individuals under the age of 70 years who had premature death due to non-
communicable disease in 2015, 82% were from low and middle income countries, and 
37% of these were due to CVDs. (2) 
According to WHO in 2015, 40 million out of the 56 million global deaths were 
attributable to Non-Communicable Diseases (NCD). 48% of deaths due to non-
communicable diseases occurred before 70 years of age among low and middle 
income countries.  (3) 
According to CDC in 2014, the age-standardized death rate attributable to all 
Cardiovascular disease in the United states was 220.8 per 100 000 which had reduced 
by 14.9% from 259.4 per 100 000 in 2007. (4) 
The death rate attributable to Coronary Heart Disease in the United stated according to 
CDC in 2014 was 98.8 per 100 000 which had reduced by 23.5% from 2007 (4).  
American Heart Association in 2011 has set a goal to improve the cardiovascular 
health of all Americans by 20%, and to reduce deaths from cardiovascular disease and 
stroke by 20%, by the year 2020 (6). The cardiovascular diseases are expected to 
increase by 120% in women and 137% in men in 2020 as compared to 1990. (7) 
The data from 44 years of follow up in the original Framingham Study cohort and 20 
years of surveillance of their offspring showed that for individuals of 40 years of age, 
the lifetime risk of developing Coronary Heart Disease (CHD) is 49% and 32% in 
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men and women respectively. For individuals reaching age 70 years, the lifetime risk 
of developing Coronary Heart Disease (CHD) is 35 % and 24% in men and women 
respectively.  In individuals below 65 years of age, the annual incidence of all 
coronary events in men is 12 per 1000.  Coronary events comprise 33 - 65 % of 
atherosclerotic cardiovascular events in men and 28 - 58 % in women. (8) 
According to the GBD 2015, during 2005 to 2015, there was increase in global Cardio 
Vascular Disease (CVD) mortality by 12·5% (95% UI 10·6–14·4) while age 
standardised mortality rate due to CVD reduced by 15·6% (14·2–16·9). The reduction 
in age standardised death rate due to CVD was mainly due to declining mortality rates 
due to cerebrovascular disease (i.e., stroke; decreased by 21·0%, 19·2–22·8 since 
2005). In between 2005 to 2015, the global mortality due to IHD increased by 16·6% 
(14·6–18·6), i.e. 8·9 million deaths (8·8 million - 9·1 million), while age standardised 
mortality rates for IHD decreased by 12·8%, (11·4–14·2). In 2015, IHD and stroke 
accounted for 15·2 million deaths (15·0 million - 15·6 million), which corresponds to 
85·1% (84·7–85·5) of all deaths due to CVD. (9) 
4.2.2 Risk factors 
 
According to the Global Burden of Hypertension, the adult population in 2000 with 
Hypertension was 26·4% (95% CI 26·0–26·8%) and it is projected to increase to 
29·2% (28·8–29·7%) i.e. 1·56 billion (1·54–1·58 billion) population by 2025. It is 
expected that by 2025, 29·0% of men (28·6–29·4%) and 29·5% of women (29·1–
29·9%) will have hypertension. (10).  
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The aim of the American Heart Association is to improve the cardiovascular health by 
encouraging people to meet the seven cardiovascular health parameters- not smoking; 
being physically active; having normal blood pressure, blood glucose and total 
cholesterol levels, and weight; and eating a healthy diet.  Yang et al analysed the data 
of the patients with above metrics using data from the National Health and Nutrition 
Examination Survey (NHANES) 1988-1994, 1999-2004, and 2005-2010 and the 
NHANES III Linked Mortality File (through 2006) and found that the adjusted 
population attributable factor for Cardio Vascular mortality was 40.6% (95% CI, 
24.5%–54.6%) for High Blood Pressure, 13.7% (95% CI, 4.8%–22.3%) for smoking, 
13.2% (95% CI, 3.5%–29.2%) for poor diet,  and 8.8% (95% CI, 2.1%–15.4%) for 
abnormal glucose Levels (13). 
The data from the PURE (Prospective Urban and Rural Epidemiological Study) study 
was analysed to assess the prevalence of lifestyle, eating habits and physical activity 
among individuals with CHD and Stroke. International Physical Activity 
Questionnaire (IPAQ) or regional questionnaires was used to assess the physical 
activity. Among individuals with self-reported CHD (past event: median, 5.0 [ IQR, 
2.0-10.0] years ago) or stroke (past event, median, 4.0 [IQR, 2.0-8.0] years ago), one-
third (35.1%; 95% CI, 29.6%-41.0%) individuals undertook high levels of work or 
leisure related physical activities, healthy dietary habits was seen in 39.0% (95% CI, 
30.0%-48.7%) and 18.5% (95% CI, 17.6%-19.4%) continued to smoke. All the three-
healthy lifestyle behaviours was seen in only 4.3% (95% CI, 3.1%-5.8%) individuals 
while none of the healthy life style behaviours was seen in 14.3% (95% CI, 11.7%-
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17.3 There was increasing trend of level of physical activity with increasing country 
income but this was not significant statistically. (14) 
PURE study showed that Low Income Countries (LIC) had the lowest prevalence of 
eating healthy diets [25.8%; 95% CI, 13.0%-44.8%] as compared with Low Middle-
Income Countries (LMIC) [43.2%; 95% CI, 30.0%-57.4%], Upper Middle-Income 
Countries (UMIC) [45.1%, 95% CI, 30.9%-60.1%], and High-Income Countries 
(HIC) [43.4%, 95% CI, 21.0%-68.7%].  52.5% (95% CI, 50.7%-54.3%) individuals 
quit smoking, highest was seen in HIC (74.9%, 95% CI, 71.1%-78.6%) while lowest 
in the LIC in the 38.1% [95% CI, 33.1%-43.2%]. (14) 
A metaanalysis was done to assess the lifetime risks of death from CVD. The study 
showed that lifetime risks for death due to CVD was higher among men than women 
but was similar between the blacks and whites (white men: 36.1%; black men: 33.0%; 
white women: 26.6%; black women: 27.1%). Individual who were 55 years of age, 
with an optimal risk factor profile i.e. total cholesterol level <180 mg/dl, blood 
pressure less than or equal to 120/80 mm Hg, non-smokers, and non-diabetics had 
substantially lower risks of death from CVD through the age of 80 years as compared 
to participants with two or more risk factors (4.7% vs. 29.6% among men, 6.4% vs. 
20.5% among women). The lifetime risk of cardiovascular event in individuals at 45 
years of age with optimal risk factor profiles was lower as compared to those with one 
major risk factor (Men: 1.4% versus 39.6%, Women: 4.1% versus 20.2%). Individuals 
with optimal risk factor profile had lower lifetime risks of fatal coronary heart disease 
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or nonfatal myocardial infarction ( Men : 3.6% vs. 37.5%, Women : <1% vs. 18.3%) 
and fatal or nonfatal stroke ( Men : 2.3% vs. 8.3%, Women: 5.3% vs. 10.7%). (15) 
Globally, under a Business as Usual (BAU) scenario, the probability of death between 
30 - 70 years of age from the four main NCDs (all CVDs, all cancers, Chronic 
respiratory diseases and Diabetes) is expected to decrease by 0·025 (11%) between 
2010 and 2025 for men and by 0·016 (10%) for women. Despite the reduction in 
probability of death, deaths due to these four NCDs will rise from 28·3 million in 
2010 to 38·8 million in 2025, due to population growth and ageing. Out of 10·5 
million additional deaths, 3·1 million will occur before the age of 70 years while 7·3 
million in older people. A great proportion of these additional deaths will be in low 
and middle-income countries. In individuals less than 70 years of age in low and 
middle income countries, number of deaths is expected to increase by 3·2 million. 
(16) 
4.2.3 Health in urban and rural geographical distribution 
During the past, few decades there is a significant urbanisation which is contributing 
to environmental changes. In 1950, in the high-income countries, majority of the 
population (57 per cent) resided in urban areas. According to the WHO, 70% of the 
world’s population will be residing in towns and cities by 2050.  World Health Day is 
celebrated on 7th April every year, in 2010 the theme was “urbanization and health” to 
recognise the effect of urbanization on the health of the global population.  The aim 
was to encourage the leaders and the citizens to take steps to improve policies, 
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attitudes and behaviour due to negative aspects associated with urbanisation on the 
global health. (17) 
PURE (Prospective Urban and Rural Epidemiological Study) study was done in 17 
low, middle and high-income countries around the world. India constituted for 83% of 
the low-income country participants. The aim of the study was to assess the 
relationship of societal influences on human lifestyle behaviours, cardiovascular risk 
factors, and incidence of chronic noncommunicable diseases. In urban areas as 
compared to rural areas, the rate of major cardiovascular events was lower (4.83 
events vs. 6.25 events per 1000 person-years, P<0.001). (18) 
4.2.4 Education 
According to PURE study,  less than 23.8% have primary education, 21.8% complete 
primary education, 39.2% complete secondary and 15.2% complete higher education. 
(19) 
4.2.5 Economy of the country  
In PURE study, India constituted for 83% of the low-income country participants. An 
INTERHEART Risk Score was calculated to assess the risk factor burden for 
cardiovascular diseases, it was highest in HIC (12.89; 95% [CI], 12.79 - 12.98), 
intermediate in MIC (10.47; 95% CI, 10.43 to 10.50), and lowest in LIC (8.28; 95% 
CI, 8.23 to 8.34). Rural areas as compared to urban areas in high income countries 
(13.43 vs. 12.67, P<0.001), had a higher INTERHEART Risk. The INTERHEART 
24 | P a g e  
 
Risk score was lower in rural areas as compared to urban areas in MIC (10.11 vs. 
10.81) and in LIC (7.57 vs. 9.09). (18) 
4.2.6 Cardioprotective medications 
 
According to PURE study, among the individuals who were not known to have 
cardiovascular diseases, the use of cardio protective medications was highest among 
the HIC wile lowest in LIC. Antiplatelet medications use was highest in high income 
countries (8.1%, 2.8%, and 0.5%, among individuals of HIC, MIC, LIC countries 
respectively ); similarly beta blockers use was highest in high income countries  
(4.5%, 3.0%, and 1.8%, among individuals of  HIC, MIC and LIC countries 
respectively), renin–angiotensin system blockers use was highest in high income 
countries (10.5%, 4.8%, and 0.8%, among individuals of HIC, MIC and LIC countries 
respectively ), and statins were used by 10.3%, 1.6%, and 0.3% among individuals of 
HIC, MIC and LIC countries respectively. (18) 
The data from PURE study was analysed to assess the information about availability 
and costs of cardiovascular disease (CVD) medications (aspirin, β blockers, ACE 
inhibitors and statins). The availability of four CVD medications was 95% & 90% of 
urban & rural communities respectively in HIC, 80% & 73 % of urban & rural 
communities respectively in upper middle-income countries(UMIC), 62% & 37% of 
urban & rural communities respectively in lower middle-income countries(LMIC), 
25% & 3% of urban & rural communities respectively in LIC (excluding India). In 
India, the availability of four CVD medications was 89% in urban and 81% in rural 
communities. The four CVD medications were potentially unaffordable for 0·14%, 
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25%, 33% and 60% households of HIC, UMIC, LMIC and LIC (excluding India) 
respectively. In India, CVD medications were potentially unaffordable for 59% 
households. (21) 
UMPIRE trial - Use of a Multidrug Pill in Reducing Cardiovascular Event, is a 
multinational study done in India and 3 European countries (England, Ireland, and the 
Netherlands). It was a randomized, open-label, blinded-end-point trial. Fixed Dose 
Combination delivery included aspirin, statins, and two blood pressure lowering 
agents.  It was designed to assess whether Fixed Dose Combination delivery vs. usual 
care improves long term adherence to indicated therapy and 2 major CVD risk factors, 
systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C). The 
adherence was higher in FDC then with usual care (86% vs. 65%; relative risk [RR] 
1.33; 95% CI, 1.26-1.41). In the FDC group there was concurrent reductions in SBP (-
2.6 mm Hg; 95% CI, -4.0 to -1.1 mm Hg and LDL-C (-4.2 mg/dL; 95% CI, -6.6 to -
1.9 mg/dL) at the end of study period. This study demonstrated 33% better adherence 
with the polypill in comparison with the standard treatment. (22) 
4.2.7 Cost of Cardiovascular disease 
 
The benefits of treating cardiovascular risk factors are well known. A cost 
effectiveness analysis was done to assess the effect of multidrug regimen in 
preventing CVD in the developing world. Two combination regimens were used. For 
primary prevention, aspirin, calcium channel blocker, ACE inhibitor, and statin was 
used. For secondary prevention, above same regimen was used but β blocker was 
substituted for calcium channel blocker.  Across six developing World Bank regions, 
26 | P a g e  
 
primary prevention yielded ICERs (incremental cost-effectiveness ratios) of US$746–
890/QALY and $1039–1221/QALY gained for individuals with a 10-year absolute 
risk of cardiovascular disease greater than 25% and 5% respectively.  For secondary 
prevention, ICERs was $306/QALY to $388/QALY gained.  In individuals with 10-
year absolute risk for CVD of more than 5 %, primary prevention strategy resulted in 
42–57% reduction in lifetime risk of death due to CVD. This study demonstrated 
ICERs of a multidrug regimen for secondary prevention and high-risk primary 
prevention. (23) 
According to the AHA, by 2030 in the United States, 43.9% of the population is 
projected to have some form of CVD. The cost analysis includes direct and indirect 
medical costs. It is estimated that the total direct medical cost due to CVD between 
2012 and 2030 is projected to increase from $396 billion to $918 billion (2012 $ in 
billions). Among this total cost, hospital costs will account for 60.5%, cost of 
medications account for 15.6%, physician costs will account for 10.8%, nursing home 
care costs will account for be 6.8%, home health care costs will account for 5.3% and 
1.1% will attribute to other costs. The indirect costs which includes costs due to lost 
productivity for all CVDs is projected to increase from $183 billion in 2012 to $290 
billion in 2030 (2012 $ in billions), which accounts to increase of 58%. (24) 
4.2.8 Outcome 
 
In PURE study, the mean duration of follow up was 4.1 years and during the follow 
up 1.1% had myocardial infarction, 0.9% had stroke, and 0.3% had heart failure. 
Approximately 3% of the population had at least one cardiovascular event, 2.3% had 
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at least one major cardiovascular event while 0.8% had nonmajor cardiovascular 
events. The rate of major cardiovascular events was like the mortality trend with rates 
of 3.99, 5.38, and 6.43 events per 1000-person years in high, middle, and low-income 
countries respectively. The case fatality rate due to major CVD was higher in low 
(India) and middle-income countries as compared to high-income countries (6.50%, 
15.86% and 17.28% in HIC, MIC and LIC countries respectively). Urban population 
had lower major cardiovascular events then rural population (4.83 events vs. 6.25 
events per 1000 person-years). (18) 
In PURE study, in low income countries, 80% of the participants with CVD were not 
on any of the 4 secondary prevention drugs (aspirin, β-blocker, ACE inhibitors, and 
statins) as compared to 11% of participants from high-income countries. (20) 
4.2.9 Prevention of cardiovascular disease 
 
In 2013 World Health Organisation which includes all the Member countries (194 
countries) decided to innovate methods to reduce the avoidable Non-Communicable 
Disease burden including a "Global action plan for the prevention and control of 
NCDs 2013-2020". Two of the global targets directly focus on preventing and 
controlling CVDs.  The aim of this plan is to reduce the number of premature deaths 
from NCDs by 25% by 2025 through nine voluntary global targets. According to the 
Global NCD action plan, sixth target warrants a 25% relative reduction in the 
prevalence of raised blood pressure or contain the prevalence of raised blood pressure, 
according to national circumstances. The eighth target warrants the countries that at 
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least 50% of eligible people receive drug therapy and counselling (including 
glycaemic control) to prevent heart attacks and strokes. (25) 
If the targets are met, it is projected that the premature deaths attributable to CVDs in 
2025 will be reduced by 34%, with 11.4 million and 15.9 million deaths delayed or 
prevented in those aged 30 to 69 years and ≥70 years, respectively. (26) 
4.2.10 Secondary prevention 
 
In PURE study, the data of individuals with a prior coronary heart disease or stroke 
was analysed to assess the use of proven effective secondary preventive drugs 
(antiplatelet drugs, β blockers, ACE inhibitors or ARBs, and statins). The study 
showed that the individuals with prior CVD, antiplatelet drugs was used by25·3%, 
beta blockers was used by 17·4%, ACE inhibitors or ARBs was used by19·5% and 
statins was used by 14·6%. The use of  medications for secondary prevention was 
highest in HIC (antiplatelet drugs 62·0%, β blockers 40·0%, ACE inhibitors or ARBs 
49·8%, and statins 66·5%) and lowest in LIC (antiplatelet drugs 8·8%, beta blockers 
9·7%, ACE inhibitors or ARBs 5·2%, and statins 3·3%). (20) 
In PURE study, the drug utilization decreased in accordance to the economic status of 
the country. Individuals who did not receive any drug was11.2%, 45.1%, 69.3% and 
80.2% in high income, upper middle income, lower middle income and low-income 
countries respectively.  The use of drugs was higher in urban as compared to rural 
areas (antiplatelet drugs: 28·7% urban vs. 21·3% rural, β blockers 23·5% vs. 15·6%, 
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ACE inhibitors or ARBs 22·8% vs. 15·5%, and statins 19·9% vs. 11·6% in urban and 
rural areas respectively. (20) 
4.2.11 Burden of disease 
 
A systematic analysis of the GBD study 2015 was done to estimate the incidence, 
prevalence, and years lived with disability for diseases and injuries at different levels. 
During 2005 to 2015, the incidence of IHD increased by 15·5% (95% UI, 14·3- 16·8), 
while prevalence increased by 25·9% (95% UI, 24·6 - 27·2). During 2005 to 2015, 
CVDs accounted for 25.62 million years (95% UI, 18.4-33.65) of YLDS, a 23·5% 
(95% UI, 1·7 to 24·5) rise. Between 2005 to 2015, IHD prevalence increased by 
25·9% (95% UI, 24·6 to 27.2), age standardised rate reduced by 3·4% (95% UI, –4·2 
to –2·6), YLDs in 2015 was 7.27 million years (95% UI, 4.95–9.94), a 30·2% (29·1 to 
31·3) increase from 2005 to 2015, the ASR reduced by –0·3 (95% UI, –1·0 to 0·3). 
Myocardial infarction episodes accounted for 15.93 million (95% UI, 14.1 to 17. 76) 
YLDs, a 6·4% increase (95% UI, 1·9 to 10·6) between 2005 and 2015. Angina due to 
IHD accounted for 4.79 million (95% UI, 3.1–6.63) YLDs, a 29·5% (95% UI, 27·8 to 
31·0) increase between 2005 and 2015, while ASR did not show any change. (27) 
Healthy life expectancy (HALE) and disability adjusted life years (DALYs) provide 
information about the health status across regions which can help to assess the health 
system, prioritise investments in development and research, and monitor development 
towards the Sustainable Development Goals (SDGs).  
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A systematic analysis of the GBD 2015 data was done to assess the HALE and 
DALYs. The DALYs due to NCDs in 2005 was 1·1 billion (95% uncertainty intervals 
(UIs), 1·0–1·2) which increased to 1·5 billion (95% UI, 1·3–1·7) in 2015. The 
DALYs due to Cardiovascular diseases in 2005 was 3.26 billion (95% UI, 3.18- 3.34), 
in 2015 which increased to 3.47 billion (95% UI, 3.37- 3.58), an increase by 6·5% 
(95% UI, 4·1- 8·7). The DALYs due to Ischemic heart disease in 2005 was 1.47 
billion (95% UI, 1.44 - 1.51) which increased to 1.64 billion (95% UI, 1.59 - 1.69), an 
increase in 11·0% (95% UI, 8·3 - 13·3). (28) 
4.3Acute Coronary Syndrome 
4.3.1Global data  
 
There has been decline in STEMI over the past decade. National Registry of 
Myocardial Infarction is a prospective observational study which was done in United 
States from1990 to 2006. In between 1994 and 2006 the proportion of Non STEMI 
increased from 25.33 % to 59.1 % while the proportion of STEMI reduced from 
74.6% to 41.03%.  From 1990 to 2006, there was increase in mean age from 64.1 to 
66.4 years, in males from 61.8 to 63.7 years while in females from 69.1 to 71.0 years. 
The proportion of women increased from 32.4% to 37.0%. The in Hospital mortality 
in 1994 was 10.4% which reduced to 6.3% in 2006, in STEMI group it reduced from 
11.5% to 8.0% while in Non STEMI it reduced from 7.1% to 5.2%. (29) 
Prior to 2000, CKMB was used for diagnosis of myocardial infarction.  To assess the 
effect of troponin T on the incidence and outcome in MI, a community based study 
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was done in Olmsted County, during 1987 to 2006. It included prospective 
measurements of troponin and CKMB from August 2000 onwards. 59.9 % MI 
occurred prior to the introduction of Troponin T, among these, 25% did not meet the 
criteria as defined by CKMB and met only troponin based criteria.  The mean age of 
MI was 68.3±14.9, 72.7±14.3 on considering only Troponin T while 67.9±15.1 on 
considering only CKMB. 43% individuals were women, 39% individuals were 75 
years of age or older.  Non STEMI was seen in 69% individuals. The diagnosis of Non 
STEMI was made in 93% if Troponin T was considered while in only 71% when 
CKMB was considered. The incidence of STEMI declined by 41% irrespective of 
troponins (RR - 0.59, 95% CI, 0.47 - 0.76 for STEMI on including troponin only 
cases, vs. 0.56, 95% CI, 0.44 - 0.71 for STEMI excluding troponin only cases). The 
incidence rates of Non STEMI increased by 49% when troponin only cases were 
included (RR 1.49, 95% CI, 1.23 - 1.81). As compared to 1987, in 2006 the age and 
sex adjusted hazard ratio for 30-day mortality was 0.44 (95% CI, 0.30 - 0.64), a 56% 
decline in two decades. This study showed that the incidence of Non STEMI had 
increased after the introduction of Troponin T. (30) 
The INTERHEART study is a multinational study, done in 52 countries of the world; 
India was included in the South Asia region. It is a case control study of acute 
myocardial infarction which was done to assess the relationship of smoking, history of 
hypertension or diabetes, waist/hip ratio, dietary patterns, physical activity, 
consumption of alcohol, blood apolipoproteins (Apo), and psychosocial factors to 
myocardial infarction. (31) 
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The Second Euro Heart Survey on Acute Coronary Syndrome (EHS-ACS-II) is a 
prospective study done at 32 countries in Europe and the Mediterranean basin. (32) 
The Global Registry of Acute Coronary Events (GRACE) is a prospective, 
multinational study done in 14 countries and involved 95 hospitals, individuals with 
acute coronary syndrome were organized into 18 population based clusters. (33) 
Worcester Heart Attack study was done in Worcester; it is a30 years (1975–2005) 
perspective of patients admitted with acute myocardial infarction. (34) 
4.3.2 Baseline characteristics  
 
In the INTERHEART study, age at which first acute myocardial infarction was 
reported was younger in South Asia (53 years median age, 46-61 years) and the 
Middle East (51 years median age, 45-59 years) while the oldest patients were from 
western Europe, China, and Hong Kong (63 years median age).  In South Asia, 8.9% 
individuals at presentation were less than 40 years of age, Men were 9.7% and women 
were 4.4%.  (31) 
In EHS-ACS-II study, 47% had STEMI, 48% had Non STEMI while 5% had 
undetermined electrocardiographic pattern. The mean age was 62.5±13.1 years among 
the STEMI, 66.1±12.1 years among NSTEMI. There was male predominance with 
74.1% and 67% among the STEMI and Non STEMI respectively. There was prior 
myocardial infarction in 15.7% and 29.3% among STEMI and NSTEMI respectively. 
As compared to 2000, in 2004 the number of patients hospitalised in coronary care 
units increase (70% vs. 62.4%), while less patients were treated in cardiology wards 
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(19.1% vs. 22%), and in internal medicine wards (7% vs. 13.8%), other wards (3.9% 
vs. 1.8%). There was reduction in the median time from onset of symptoms to arrival 
at the emergency department, from 210 min (105–625) in 2000 to 170 min (90–420) 
in 2004. (32) 
In GRACE registry, the diagnosis at admission was unstable angina in 44%, 
myocardial infarction in 36%, 9% individuals were admitted to rule out a myocardial 
infarction, 7% had chest pain and remaining 4% were hospitalized for other cardiac or 
non-cardiac aetiology. Age was less than 55 years in 27%, 20% and 22% of STEMI, 
Non STEMI and unstable angina respectively.  The final diagnosis in the study 
population was, STEMI in 30%, Non STEMI in 25%, unstable angina in 38%, other 
cardiac or non-cardiac in 7%. (33) 
In Worcester Heart Attack study, in 2005 the mean age was 70.8 (+14.6) years. There 
were 51.7 % men and 95% were Caucasian. Q wave AMI was seen in 22.7%, STEMI 
was seen in 36.1%. The age of patients who were admitted for initial AMI were older 
in 2005 then 1975, the age of AMI was 63.5 years(mean) in 1975 while 70.8 years 
(mean) in 2005. The length of hospitalisation was 5.3 (+5.0) days; time of onset of 
symptoms to hospitalisation was 1.9 hours (median). Diabetes mellitus was seen in 
28.3% individuals, hypertension in 72.0%, while 23% were current smokers. The 
incidence rate of initial acute myocardial infarction in 2005 was 209/100000 
population which was lower than as seen in 1975, 277/100000, though variations were 
seen. (34) 
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4.3.3 Risk factors 
In the INTERHEART study, the number of smoked years and risk of myocardial 
infarction showed a strong and graded relation, with every increment the risk 
increased, individuals smoking greater than 40 cigarettes per day had an odds ratio of 
9·16 (99% CI, 6·18–13·58). The odds ratio for acute myocardial infarction in 
individuals who are current smokers, hypertension, and diabetes was 13·01 (99% CI, 
10·69–15·83) as compared to those without these risk factors. Current smoking, 
Hypertension and Diabetes accounted for 53% of the PAR (population attributable 
risk) for acute myocardial infarction. (31) 
EHS-ACS-II the study, Diabetes mellitus was there among 21.4% and 26.7% of 
STEMI and Non STEMI respectively, Hypertension was there in 50.0% and 64.6%, 
dyslipidaemia in 43.2% and 51.9%, individuals who were current smokers were 
45.6% and 28.0%, past smokers were 22.6% and 29.8%, among STEMI and Non 
STEMI respectively. (32) 
In GRACE registry, Individuals who were current smokers or history of smoking was 
62%, 57% and 54 %, Diabetes Mellitus in 21%, 27% and 25%, Hypertension in 50%, 
59% and 65% of STEMI, Non STEMI and unstable angina respectively. (33) 
4.3.4 In hospital management 
 
In EHS-ACS-II, the medications used were, Aspirin in 96.8 % and  94.5% of STEMI 
and NSTEMI respectively, Ticlopidine/ clopidogrel in 69.8% and  67.4%, Statins in 
80.7% and 73.7%, ACE/ARB in 75.4% and 69.5%, IV/oral beta blocker in 83.0% and  
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82.8%, Heparin/LMWH in 77.2% and 72.9%, among the STEMI and NSTEMI 
respectively. (32) 
In GRACE registry, medications use among STEMI, Non STEMI and unstable angina 
was, Aspirin in 95%, 91% and 90% of STEMI, Non STEMI and unstable angina 
respectively, ticlopidine/clopidogrel in 37%, 29% and 21%, beta blocker is 81%, 78% 
and 74%, unfractioned heparin in 66%, 61% and 47%, ACE inhibitors in 66%, 55% 
and 50%, oral or topical nitrates in 58%, 72% and 81%, thrombolytic agents in 47%, 
5% and 4% of STEMI, Non STEMI and unstable angina respectively. Percutaneous 
coronary intervention was done in 6%, 13% and 20% of STEMI, Non STEMI and 
unstable angina respectively. (33) 
4.3.5 Discharge advice 
 
In GRACE registry, the discharge medications used among STEMI, Non-STEMI/UA 
respectively were, Aspirin in 89%, 86% and 86% of  STEMI, Non-STEMI/UA 
respectively, ticlopidine/clopidogrel in 36%, 28% and 20%, %, beta blocker is 72%, 
69% and 66%, ACE inhibitors in 60%, 49% and 46%, statins in 48%, 46% and 46%, 
oral nitrates in 36%, 49% and 63% among STEMI, Non-STEMI/UA respectively. (33) 
4.3.6 Outcome 
 
In EHS-ACS-II study, the most common complication during hospitalization was 
heart failure (12.4%) while other complications were re-ischemia/re-infarction (8.0%), 
and paroxysmal or persistent atrial fibrillation (AF) (3.3%). The in-hospital mortality 
and 30-day mortality was 4.0% and 5.1% respectively. The data for 30 days follow up 
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was available for 85% of hospital survivors. The 30-day mortality was 5.1%. The rate 
of rehospitalisation during the first month was 15.9%. The reason for re 
hospitalizations among STEMI and Non STEMI was due to need for coronary 
angiography (4.4% and 4.8%), PCI (2.9% and 2.7%), coronary artery bypass surgery 
(CABG) (1.5% and 2.0%), or other cardiac surgery (0.3% and 0.2%) respectively. 
(32) 
In GRACE registry, in hospital mortality was seen in 7%, 6% and 3% of STEMI, Non 
STEMI and unstable angina respectively. Reinfarction was seen in 3% and 2% of 
STEMI and Non STEMI respectively. (33) 
In the Worcester Heart Attack study, the in-hospital mortality was 19.1% while in 
2005 it was 9.5%. The 30 day mortality in 1975/78 was 17.6% which reduced to 
11.9% in 2003/05. (34) 
4.3.7 Acute Coronary Syndrome management in general medical wards 
A prospective observational study was done in Sri Lanka to assess the management of 
ACS in a tertiary care medical ward. There were 101 admissions which were 
confirmed to have ACS. The correct loading dose of aspirin and clopidogrel was not 
given to 30.6% and 39.6% patients respectively.  STEMI was diagnosed in 34 
(33.66%) patients, 26(76.5%) patients were eligible for thrombolysis, Streptokinase 
was given to 22 (84.6%). Among the remaining 67 patients, the correct dose of 
LMWH was received by 66 patients. At presentation, 51.4% patients were initiated on 
beta blocker, 73.2% were initiated on either an ACE inhibitor or an ARB.  
Percutaneous Coronary Intervention was done in none of the patients. (35) 
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4.3.8 Scores to assess morbidity and mortality 
For individuals with STEMI who were eligible for fibrinolytic therapy, a clinical risk 
score was developed to predict 30-day mortality at presentation. The mean 30-day 
mortality was 6.7%. The TIMI risk score is composed of ten baseline variables which 
account for 97% of the predictive capacity of the multivariate model. There was >40 
times graded increase in mortality, for scores from 0 to >8, in individuals with score 0; 
the mortality was less than 1%. Among the deaths by 30 days, 36% occurred in the 
first 24 hours while 56% death occurred by 72 hours, and 91% by hospital discharge. 
The table below shows the mortality patters for STEMI. (36) 
  
The TIMI risk score for Non STEMI/ UA were derived from a cohort by selecting 
independent prognostic variables by using multivariate logistic regression.  The 7 
TIMI risk score predictor variables were: age >/= 65 years, at least 3 risk factors for 
CAD, prior coronary stenosis of 50% or more, deviation of ST segment on ECG at 
presentation, at least 2 anginal events in prior 24 hours, use of aspirin in prior 7 days, 
and elevated serum cardiac markers.  The event rates increased as the TIMI risk score 
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increased, 4.7% for a score of 0/1 to 40.9% for score 6/7. TIMI model for NSTEMI/ 
UA is shown below. (37) 
 
The data from the GRACE registry was analysed to calculate GRACE score (hospital 
discharge risk score) to predict mortality beyond six months among the patients with 
acute coronary event. The mortality was 7.5% during index admission, 12.1% at 6 
months, 14.8% at 1 year, 18.7% at 2 years, 25.0% at 3 years, and 39.2% at 4 years the 
C index was calculated using the GRACE cohort as mentioned below. (38) 
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4.4Cardiovascular Diseases in India 
4.4.1 Epidemiology 
 
According to WHO, in 2010 NCDs led to 5.87 million deaths globally.  In India, there 
were 1.2 million deaths in men and 0.9 million deaths in women due to NCDs. The 
death rate in India is higher than many other countries of the world except China. 
According to WHO, the South Asian region has one of the highest cardiovascular 
mortality rates in the world.  In India, the age adjusted CVD mortality rates are 
349/100,000 in men and 265/100,000 in women. These rates are more than 2-3 times 
than in the United States, where CVD mortality rates are 170/100,000 in men and 
108/100,000 in women. (39) 
According to the Global Burden of Disease 2015, the Indian data shows that during 
the period of 1990 to 2015 there is increase in life expectancy between from 58 years 
to 65.8 years among men and 60.5 years to 71 years among women. As a 
consequences of increased life expectancy, there is ageing of the population with 
subsequent increase in the non-communicable diseases. The increased burden of non-
communicable disease is attributed to cardiovascular disease. During  2005 to 2015, 
IHD was the most common aetiology of all cause death and premature death and there 
is increase of 16.7% and 11.1% death respectively. (40) 
In developed countries, age standardized cardiovascular disease death rates (per lakh 
population) in individuals of age group 30–69 years is low, Canada (120), Britain 
(180) while in developing countries it is high Brazil (320), China (280), Pakistan 
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(400), Nigeria (410), Russia (680). In India the standardized cardiovascular disease 
death rates is 405/100000 population. (41) 
According to the Registrar General of India, in 2015 Circulatory diseases contributed 
to 33.2% of medically certified deaths, 32.8 % and 33.9 % among men and women 
respectively. 26.9% deaths were due to Ischemic Heart Diseases (IHD) (42). In India, 
NCD death rate, age standardised was 600 per one lakh population. In our country, 
56% of NCD death occurred before 70 years of age. (3) 
In India, among the people of age group 35–64 years, there is significant loss of 
potentially productive years of life due to deaths from cardiovascular disease, 9·2 
million years lost in 2000.  By 2030 it is projected that the loss is expected to rise to 
17·9 million years which is 940% greater than the corresponding loss in the USA. (7) 
The Prospective Study of One Million Deaths in India was done during 2001 to 2003 
by using a validated verbal autopsy instrument. The existing sample registration 
surveys of the government of India were considered and more than 120,000 death 
reports which were obtained from 661 districts of the country were evaluated by using 
a nationally representative sample of more than 6 million participants. The verbal 
autopsy showed that death due to vascular aetiology was seen in 41% men and 37% 
women. In Tamilnadu, 25.8% death was due to vascular aetiology. CVD was the most 
important aetiology of death among  men and women, in urban and rural populations. 
(43) 
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4.4.2Risk factors 
An observation study was done by Gupta et al, in two Indian cities - Raipur and New 
Delhi to assess the age specific trends in cardiovascular risk factors among the 
adolescent and young. The study revealed that cardiovascular risk factors increase 
exponentially with age among Indians once they reach age group of 30- to 39 years. 
(44) 
To assess the prevalence of diabetes in India, in collaboration with the Indian Council 
of Medical Research, ICMR India DIAbetes (ICMR INDIAB) study was designed.  In 
the phase one of the study, four regions were studied and Tamilnadu was one of the 
regions. According to the phase one study, the weighted prevalence of diabetes in 
Tamilnadu was 10.4%, with prevalence in urban areas 13.7% and 7.8% in rural areas. 
The prevalence of metabolic syndrome ranged from 16.7% to 41.7% in urban areas to 
8.5% to 25.8% in rural areas. There was higher prevalence of metabolic syndrome in 
urban areas except Maharashtra. In Tamilnadu, the major oil for cooking in urban and 
rural areas were Sunflower oil (40.0% ) and  groundnut oil ( 39.7 ) respectively, the 
other oils used for cooking were palm oil, Gingelly oil and others. (45) 
The prevalence for hypertension in India according to a metaanalysis was 29.8% (95% 
CI: 26.7–33.0). There was higher prevalence in urban areas as compared to rural 
areas, 27.6% (23.2–32.0) and 33.8% (29.7–37.8) respectively. Among the individuals 
who were known to have Hypertension, 25% in rural and 42% in urban areas were 
aware of their hypertension status. 25% population in rural and 38% population in 
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urban areas are being treated for Hypertension. One tenth of rural population and one 
fifth of urban population had their blood pressure under control. (46) 
According to the Global Adult Tobacco Survey 2 (GATS 2), done in 2016-2017, by 
the Ministry of health and family welfare, Government of India, among adults who are 
more than 15 years of age, tobacco use in any form is seen in 28.6% of them. Tobacco 
consumption is higher in rural India as compared to urban India, 19.9 crores vs. 6.8 
crores respectively. 14.8 crore rural men and 5.4 crore urban men are tobacco 
consumers. The number of tobacco users has reduced by 81 lakhs as compared to 
2009-2010. The prevalence of tobacco consumption among the population 15-24 
years of age has reduced from 18.4% in GATS 1 to 12.4% in GATS 2. (47) 
Obesity and overweight are important risk factors associated with coronary heart 
disease. To assess the differences in the body mass index and waist hip ratio among 
the urban and rural population in North India, a cross-sectional study was done in 
urban Delhi and rural Ballabgarh. The study showed that among the surveyed urban 
men, 35.1% had a BMI of ≥ 25.  Among the surveyed urban women, 47.6% were 
overweight, among whom BMI of ≥ 30 was seen in 16.4%. As compared to urban 
population, among the surveyed rural population, 7.7% of men and 11.3% women 
were overweight.  In the rural men and women, one third had a BMI less than 18.5 i.e. 
were underweight. (48) 
Physical activity is necessary to prevent cardiovascular morbidity and mortality. In the 
ICMR INDIAB study, the physical activity was assessed using a Global Physical 
Activity Questionnaire (GPAQ). The study showed higher level of inactivity in urban 
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population (65%) as compared to rural population (50%). Similar trends were seen in 
Tamil Nadu, where 71% of urban residents were inactive as compared to 55.4% of 
rural residents.  In both urban and rural areas, men were more active as compared to 
women. There was absence of any recreational activity in a significant high proportion 
of Indians, with only less than 10% of the individuals having a recreational physical 
activity.  Region wise data showed  absence of any form of recreational physical 
activity in 88.4%, 94.8%, 91.3% and 93.1% of  individuals in Chandigarh, Jharkhand, 
Maharashtra and Tamilnadu respectively. (49) 
In the ICMR INDIAB study, dyslipidaemia was studied which showed that among the 
participants, 13.9% had hypercholesterolemia, 29.5% had hypertriglyceridemia, 
72.3% had low HDL-C, 11.8% had high LDL-C levels. The most common lipid 
abnormality was Low HDL-C (72.3%) in all the four regions. At least one lipid profile 
parameter was abnormal in 79% individuals. Tamilnadu had the highest rates of 
hypercholesterolemia (18.3%) and LDL-C (15.8%). (50) 
A case control study was done in New Delhi and Bangalore to study the association 
between diet and Ischemic Heart Disease risk in India. In the multivariate analysis, the 
inverse association was greater for green leafy vegetables; individuals who consumed 
a median of 3.5 servings/week had a 67% lower relative risk (RR: 0.33; 95% CI: 0.17, 
0.64) than individuals who consume 0.5 servings/week (51). 
4.4.3 Cardioprotective medications 
The data from PURE study was analysed to assess the information about availability 
and costs of cardiovascular disease medications (aspirin, β blockers, ACE inhibitors 
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and statins). In India, the availability of four cardiovascular medications was 89% in 
urban and 81% in rural communities. In India, cardiovascular disease medications 
were potentially unaffordable for 59% households. (21) 
In Rajasthan, a study was done to determine the frequency of use of pharmacotherapy 
with aspirin, beta blocker, statin, and ACE inhibitor in patients with CHD among 
physicians at different levels of health care. Physicians were contacted who were 
practicing at tertiary hospitals and clinics at tertiary, secondary and primary levels. 
The prescriptions of CHD patients were audited. Aspirin was used in 91%, beta 
blockers in 69%, ACE inhibitors or ARB blockers in 82%, and statins in 69%.  All the 
four drugs were prescribed to only 35.5% individuals. In tertiary hospitals, all the 4 
medicines was prescribed to only 54% of  patients with coronary heart disease, while 
rates were low in secondary (28%) and primary care (7%) clinics. (52) 
4.4.4 Education 
A prospective cohort study was done in an urban setup in Mumbai to assess the 
influence of education, which is a marker of socioeconomic status on cardiovascular 
disease (CVD) mortality. The study showed that as compared to illiterate men, age-
adjusted HRs for CVD mortality in primary school to college going men was 1.36, 
1.27, 1.01 and 0.88 (p < 0.05) and in women 0.69, 0.55, 1.04 and 0.74, respectively (p 
> 0.05).  Cardiovascular disease mortality was higher in the men with low educational 
status, while association among the women was not seen. Hence education should be 
considered as an important tool to prevent cardiovascular disease mortality. (53) 
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4.4.5 Burden of disease  
A systematic analysis of the GBD 2015 data was done to assess the HALE and 
DALYs. In India in 2015, at birth the female life expectancy is 69·53 years (68·68– 
70·43), HALE is 59·44 (56·46– 62·17) while male the life expectancy is 65·24 years 
(64·46– 66·00), HALE is 56·97 (54·53– 59·20).  In India at 65 years of age, life 
expectancy is 15·06 (14·65– 15·51) and 13·21 (12·89– 13·53) among women and 
men respectively, HALE is 11·14 (10·03– 12·17) and 9·89 (9·00– 10·75) among 
women and men respectively. IHD is the leading cause of DALY with 11% increase 
during 2005 to 2015. (28) 
In India, the number of years of life lost due to coronary heart disease deaths prior to 
60 years age will increase from 7·1 million in 2004 to 17·9 million in 2030.  Despite 
the improvement in the socioeconomic conditions, it is projected that for the Indian 
population aged 45 years and older, DALYs lost due to chronic diseases will increase 
from 278 in 2004 to 307 in 2030 per thousand individuals. (54) 
Major cause of DALYS lost in India is due to Ischemic heart disease. India's 
healthcare access and quality (HAQ) index has increased from 30.7 in 1990 to 44.8 in 
2015, a cumulative increase of  14.1. (40) 
4.5 Acute Coronary Syndrome 
4.5.1 India epidemiology 
CREATE registry is a prospective study in which the treatment and outcomes of 
Acute Coronary Syndrome was studied in India. This study recruited patients from 89 
centres in 50 cities of India. (55) 
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Kerala ACS registry is a prospective study done among consecutive ACS admissions 
in 125 hospitals in Kerala during 2007 to 2009. (56) 
The DEMAT registry (Detection and Management of Coronary Heart Disease), was 
done in India between 2007- 2008, in ten tertiary care centres, our institution was one 
of the centres.  It was done to assess the association between gender, care measures, 
and outcomes in ACS in our country. (57) 
A study was done in Himachal Pradesh to assess the clinical profile and risk factor of 
female patients admitted with an AMI. (58) 
4.5.2 Baseline characteristics 
In CREATE registry, there was male predominance with males accounting for 76·4% 
of all the patients. 60.4% were diagnosed STEMI while 39.4% as Non STEMI. The 
mean age of the patients was 57·5 years, patients with STEMI were younger (56·3 
[12·1] years) as compared to those having non-STEMI or unstable angina (59·3 
[11·8].  The individuals who presented within four hours of onset of symptoms were 
38·1%, 41·2% of STEMI and 33·3% of Non STEMI. Presentation after 12 hours of 
onset of symptoms was seen in 35·4%, 30·8% of STEMI and 42·4% of Non STEMI. 
The duration of hospitalisation was ≤5 days for 57·3% patients, Non STEMI (65·7%) 
as compared to STEMI (51·8%) had shorter duration of hospitalisation. (55) 
In KERALA ACS registry, STEMI was diagnosed in 37% participants, 31% had non-
STEMI while 32% had unstable angina. The mean age of participants was 60.4 (12.1) 
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years and was similar in all the three groups. There was a male predominance with 
77.4 % participants being male. (56) 
In the DEMAT registry, 51.16% participants had STEMI while 48.37% had 
NSTEMI/UA. Among men, 55.2% had STEMI while 44.8% had NSTEMI/UA. 
Among women, 38.3% had STEMI while 61.7% had NSTEMI/UA. Age was of ACS 
was 57.2 years (SD 11.4) for Men and 60.8 (SD 10.4) for women. (57) 
In the study done in Himachal Pradesh, mean age of the participants was 62.7 ± 13.6 
years, (38-86 years). 15 (18.75%) individuals were ≤ 50 years of age, 25 (31.25%) 
individuals were between 61 to 70 years and 13 (16.25%) individuals were more than 
70 years of age. Urban population was 14 (17.5%) individuals while rural areas 
constituted 66 (82.5%) individuals. Majority of the participants, 72 (90%) were from 
areas which were more than 5 km from hospital radius.  STEMI was diagnosed in 
53.75% while 46.25% were diagnosed to have Non STEMI. Time to onset of 
symptoms to presentation was within 6 hours in only 9 (11.25%) individuals. (58) 
4.5.3 Risk factors 
In CREATE Registry, Body Mass Index was 20–24·9 kg/m2, among 52·9% 
participants. There was higher percentage of prior myocardial infarction among Non 
STEMI as compared to STEMI (26·6% vs. 11·5% respectively). 30.4% individuals 
were known to have diabetes mellitus, 26.9% among STEMI and 35.8% among Non 
STEMI. 37.7% had hypertension, 31.4 % among STEMI and 47.5% among Non 
STEMI. 27.9% participants were current smokers, 34.1% among STEMI and 18.5% 
among Non STEMI while 12.3% individuals were past smokers. (55) 
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In Kerala ACS registry, 37.6% individuals had diabetes mellitus, 34.6%, 37.9% and 
40.7% among STEMI, Non STEMI and unstable angina respectively,  48.4% 
individuals had hypertension, 55.5%,  48.2% and 40.4% among STEMI, Non STEMI 
and unstable angina respectively,  34.4% individuals had history of smoking, 35.3%, 
37.9% and 30.2% among STEMI, Non STEMI and unstable angina respectively, 
14.2% individuals had prior myocardial infarction, 13.1%, 15.4% and 14.3% among 
STEMI, Non STEMI and unstable angina respectively. (56) 
In DEMAT Registry, Hypertension was seen in 42.3% and 62% men and women 
respectively, diabetes mellitus in 37.9% and 45.5%, dyslipidaemia in 15.0 and 15.6%, 
prior coronary heart disease in 11.7% and 9.9%, current tobacco consumers in 33.1% 
and 2.1% , among men and women respectively. (57) 
Diabetes mellitus was present in 16 (20.0%), hypertension in 24 (30.0%). Among the 
participants known to have hypertension, 53.57% had optimal blood pressure. There 
was established CAD 7 (8.75%) of participants at the time of presentation, 2 (2.50%) 
had prior STEMI. (58) 
4.5.4 In hospital management 
 
In CREATE registry, the in hospital management is summarised in the table   below. 
(59) 
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 Total  STEMI NSTEMI 
In hospital management 
Antiplatelet drugs 97·9% 97·9% 97·4% 
β blockers 59·3% 57·5% 61·9% 
Lipid-lowering 
drugs 
52·0% 50·8% 53·9% 
ACE inhibitors 
/ARB 
56·8% 0·5% 51·2% 
Anticoagulants 81·3% 78·6% 85·5% 
 
Thrombolysis was done in 36·8%, 58·5% of STEMI and 3·4% of Non STEMI. 81.3% 
patients received anticoagulation, 78·6% and 85·5% among STEMI and Non STEMI 
respectively. Percutaneous Coronary Intervention was done in 7·5% patients, 8% and 
6.7% among STEMI and Non STEMI respectively. (55) 
In Kerala ACS registry, the in-hospital medications used were, Aspirin and 
clopidogrel in 93.0% and 95.1% participants respectively, beta blockers in 65.8%, 
statins in 70.0%, ACE/ ARBs in 27.8%, nitrates in 86.6%, anticoagulation in 70% 
participants. Thrombolysis was done in 41% of STEMI while 19% of non-STEMI and 
11% of unstable angina patients were thrombolysed without an indication. 
Percutaneous Coronary Interventions was done in 13% individuals with STEMI. (56) 
In DEMAT Registry, in hospital management was, Aspirin was used in 96.1% and 
93.7% among men and women respectively, Clopidogrel in 93.7 % and 92.5%, Beta 
blockers in 79.2% and 76.2%, Statins in 93.4% and 91.6%, Anticoagulation in 51.5% 
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and 52.1%, among men and women respectively. Optimal in hospital care was seen in 
37.6% men and 35.6% women. (57) 
4.5.5 Discharge advice 
In Kerala ACS Registry, discharge medications were, Aspirin and Clopidogrel was 
given to 76.4 %and 79. % participants respectively, beta blockers to 62.7 %, statins to 
70.1%, ACE/ ARBs to 25.5%, nitrates to 75.1 % participants. The registry also 
demonstrated that optimal in-hospital and discharge medical care were delivered in 
only 40% and 46% of admissions, respectively.  (56) 
In DEMAT Registry, discharge management was, Aspirin was advised to 93.9% and 
94.4% men and women respectively, Clopidogrel to 91.8% and 87.2%, Beta blocker 
to 80% and 77.3%, ACE/ ARB to 66.9% and 63.2%, Statin to 88.5% and 86.2%, 
among men and women respectively. Optimal discharge advice was seen in 64.7% 
men and 58.3% women. (57) 
4.5.6 Outcome 
In Create registry, a 30 day outcome was analysed, the data is as shown below (59) 
30-day outcome  
 STEMI NSTEMI  Unstable Angina 
Death  6·7% 8·6% 3·8% 
Reinfarction 1·9% 2·3% 1·2% 
Cardiac arrest 
(resuscitated) 
2·5% 3·4% 1·2% 
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The outcomes after ACS was worse in lower SES individuals (30-day mortality was 
8.2% for the poor as compared with 5.5% in the rich. (55) 
In Kerala ACS registry, the unadjusted in hospital mortality rate was 8.2% in STEMI, 
while lower rates were seen in non-STEMI (1.8%) and unstable angina (0.9%) group. 
Participants who had STEMI had a higher risk of in-hospital mortality [odds ratio 
(OR) of 4.06 (95% CI= 2.36- 7) and in-hospital MACE [OR = 2.75 (95% CI: 1.81- 
4.17)] than patients presenting with unstable angina.  In hospital reinfarction was 
0.5% while in hospital stroke was 0.3%. (56) 
In DEMAT Registry, at 30 days follow up, death was seen in 3.0% women and 1.8% 
men (unadjusted OR = 1.70 (0.80, 3.64). At 30 days, death, rehospitalisation, or 
cardiac arrest as a combined end point was seen in 13.5% women and 12.5%  men 
(unadjusted OR = 1.09 (0.76, 1.56). (57) 
The study done in Himachal Pradesh showed, in hospital outcome was reinfarction in 
2.5%, heart failure in 35%, stroke in 2.5% and death in 13.75%. The 30 day outcome 
was reinfarction in 4.3%,  heart failure in 7.24% while death in  5.79%. (58) 
4.6 Data from studies done in our institution 
A retrospective study was in our institution to assess the trends in reperfusion therapy 
in STEMI. Anterior wall was involved in 61% individuals, inferior wall with various 
combinations in 38%. Reperfusion therapy was received by 86% individuals, 
Streptokinase (65%) was the most common agent used, and tenecteplase was used in 
10%, while 10.7% individuals underwent Primary PCI. Late presentation (85.7%) was 
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the most common reason for not receiving reperfusion therapy. The most common age 
group was 40–59 years in 49.8% individuals, in this age group 83% were men and 
17% were women, AWMI was seen in 60% while IWMI in 38%. (60) 
4.7 Justification for the study 
Coronary heart disease is major cause of morbidity and mortality among the 
cardiovascular diseases. There is an increase in acute coronary syndrome due to raise 
in risk factors, unhealthy diet and lifestyle changes. Non STEMI, STEMI and UA 
constitute ACS. There is a rise in patients admitted in general medical wards with 
NSTEMI as compared to STEMI in our hospital. It is important to understand the 
clinical presentation, risk factors and lifestyle associated predisposing to it. There is a 
paucity of data on morbidity and mortality – in hospital and long term, in proven cases 
of acute coronary syndrome admitted to general medical wards in our institution. 
Studying the clinical presentation and identifying the predisposing factors will help in 
better understanding of the disease, early recognition of the risk which would translate 
to better outcomes and prevention of further cardiovascular events in the future. The 
risk of death or recurrent Myocardial infarction at admission will be calculated using 
the TIMI score compared with our data of morbidity and mortality. We will also 
assess whether there is any variation of outcome among patients with different 
economic strata. 
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5.Methodology  
 
5.1 Institutional Review Board Approval 
The study protocol was approved by the Institutional Review Board in January 2016 
[IRB Min No. 9821 dated 07.01.2016] (IRB approval letter in Annexure 11.1.2). The 
study was funded by the Hospital research fund-Fluid research grant n umber 22 Y 
848 (Fluid Grant approval Annexure number 11.1.3).  
 
5.2Clinical Trials Registry India number 
The Clinical Trials Registry India number is REF/2015/12/010291. 
5.3Duration of the study 
The recruitment of participants took place for 15 months, April 2016 to July 2017.  
All participants eligible were consecutively enrolled during the study period.  
5.4 Study design 
This study was a prospective observational cohort study of patients admitted with a 
proven Acute Coronary Syndrome. STROBE checklist was used for designing the 
study and reporting the outcome (Annexure 11.6) 
5.5 Setting 
This study was conducted in the Christian Medical College and Hospital, a 2695 
bedded University Teaching Institute in south India. It caters predominantly to lower 
and middle-income patients from Southern as well as North East India. The patients 
admitted under the general medical units were included in the study. 
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Patients presenting with acute chest pain are seen in the Emergency department (ED) 
or the Chest pain unit of the cardiology department. Those seen under the ED are seen 
by internal medicine. ST elevations MI’s (STEMI) are transferred to cardiology. Other 
acute coronary syndromes are managed either by cardiology or Internal medicine 
depending on the need for emergency revascularization. Those admitted as in-patients 
under general medicine are seen in the ward by cardiologist on consultation. 
5.6 Study participants 
We studied patients admitted with a diagnosis of acute coronary syndrome. The 
following were the inclusion and exclusion criteria. 
INCLUSION CRITERIA:  
o Age >/= 18 years 
• Resident of South India, preferably within 30km radius of Vellore 
• Patients living outside 30km radius of Vellore from South India, willing to 
come for follow up. 
5.7 Diagnostic criteria 
We used the following standard diagnostic criteria as defined by the European Society 
of Cardiology / American College of Cardiology / American Heart Association / 
World Heart Federation, in 2012, 
ACUTE CORONARY SYNDROME 
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According to the third universal definition, any one of the following criteria meets the 
diagnosis of acute coronary syndrome: 
• Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac 
troponin [cTn] with at least one value above the 99thpercentile upper reference 
limit [URL]) and with at least one of the following: 
o  Symptoms of ischemia 
o  Development of pathologic Q waves in the electrocardiogram (ECG) 
o  New or presumed new significant ST-segment-T wave (ST-T) changes or new 
left bundle branch block (LBBB). 
o  Identification of an intracoronary thrombus by angiography or autopsy 
o  Imaging evidence of new loss of viable myocardium or a new regional wall 
motion abnormality. 
• ST ELEVATION MYOCARDIAL INFARCTION: Clinical syndrome 
associated with characteristic symptoms of myocardial ischemia in association 
with persistent electrocardiographic (ECG) ST elevation and subsequent 
release of biomarkers of myocardial necrosis. 
o New ST elevation at the J point in at least 2 contiguous leads of 2 mm (0.2 mV) 
in men or 1.5 mm (0.15 mV) in women in leads V2–V3 and/or of 1 mm (0.1 
mV) in other contiguous chest leads or the limb leads. 
• NON- ST ELEVATION MYOCARDIAL INFARCTION 
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o ST depressions and/or T wave inversions without ST segment elevations or 
pathologic Q waves.  
o New horizontal or down-sloping ST depression ≥0.05 mV in two contiguous 
leads and/or T inversion ≥0.1 mV in two contiguous leads with prominent R 
wave or R/S ratio >1. 
• UNSTABLE ANGINA: 
o Ischemic symptoms suggestive of an acute coronary syndrome without 
elevation in biomarkers with or without ECG changes indicative of ischemia. 
5.8 Consent for participation 
The patients who fulfilled the inclusion criteria were given the study Information 
sheet. (Annexure 11.5). After they had read the same and the study explained, those 
willing gave written Informed consent. This was obtained in the regional language 
that the patient was conversant. 
5.9 Outcome 
PRIMARY OUTCOME: 
a) All-cause mortality: in hospital, one month and six months of hospital 
admission. 
Patients were asked to come for follow up at these intervals. If patients did not come 
as suggested a telephonic reminder and if required telephonic outcome assessment 
was done. 
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Deaths were classified as as coronary if this was determined by the physician at that 
admission. For those followed up via telephone we used a simple verbal autopsy. 
Those with sudden death were classified cardiac while those with prolonged illness 
such as fever, cough with sputum or other illness were classified non-cardiac.  
SECONDARY OUTCOME: 
a) Risk factors for Acute Coronary Syndrome.  
b) Association between socioeconomic strata and mortality from acute coronary 
syndromes. 
c) To determine the predictors of 1-month mortality among these patients. 
5.10Confounders 
i. Co-morbidities-Diabetes, dyslipidaemia, smoking, obesity 
ii. Pre-existing cardiac disease  
iii. Anaemia 
iv. Sepsis  
v. Renal failure  
5.11 Bias  
To reduce bias, we used standard definitions of acute coronary syndromes.  To limit 
lost to follow up we included a telephonic reminder. We collected as much data on 
confounders and potential effect modifiers as possible.  The outcome of death was 
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through confirmed hospital records or telephonic confirmation by the principle 
investigator with the immediate family members. 
5.12Sample size calculation 
According to CREATE registry the 30-day mortality for STEMI and NSTEMI is 9% 
and 4% respectively. In our study we will be seeing the patients who are admitted in 
general medical wards with Acute Coronary syndrome, the majority of that will 
include patients with NSTEMI.  
Our hypothesis is that the 30-day mortality for NSTEMI will be 6%. We expect the 
precision to be +/-3.5%. The sample size for a 5 % alpha error and 80% power with a 
precision of 3.5 % was 177. We considered a 20% drop out/ loss to follow up and our 
final sample size was 213 subjects. Sample size was calculated using the N-master 2.0 
software. The table below shows the sensitivity analysis for sample size 
Expected 
Proportion 
0.06 0.06 0.06 0.06 0.06 0.06 
Precision (%) 1 2 3 3.5 4 5 
Required 
sample size 
2256 564 241 177 135 90 
Desired 
confidence 
level (1- alpha) 
95 95 95 95 95 95 
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5.13 Data sources & measurement 
 
The data was collected from the patient or patient’s relative if the patient was unable 
to furnish the necessary information by direct interview at the time of enrolment using 
the Clinical Research Form (CRF) designed for this study (Annexure 11.2.) by the 
principal investigator.  Some of the required data required was acquired from the 
electronic health records of the hospital (Clinical Workstation, Version; Christian 
Medical College) Department of Computerized Hospital Information Processing 
Services). 
5.14Parametres 
Baseline demographics data included age, gender, hospital number, source of 
admission, date of admission and discharge, duration of hospitalisation, education, 
occupation, socioeconomic class- Modified Kuppusamy socioeconomic scale 
(Annexure 11.7).  
The Clinical presentation data included onset and duration of chest pain / 
breathlessness, NYHA class; sweating and relevant physical examination data were 
recorded. 
Data related to time of hospitalisation and time of appropriate intervention was 
assessed from the emergency medical records. Data on co-morbid illness diabetes 
mellitus, hypertension, coronary artery disease, dyslipidaemia, previous acute 
coronary syndrome were noted. 
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IPAQ (International Physical Activity Questionnaire score, smoking, alcohol 
consumption data along with dietary data, (including oil consumption) were also 
collected. 
Relevant prior medication history including antihypertensive, diabetic medications, 
anti-platelet and Statins were noted. Among those who required assisted ventilation, 
type of ventilation and duration of ventilation were observed 
All relevant investigations including ECG, Cardiac enzymes, ECHO cardiogram 
reports, medications given for the current episode and baseline TIMI score for all 
patients were collected. Complications, cardiac or non-cardiac events were obtained 
from the Discharge summary. Discharge medications and cardiac diagnostic tests 
advised (Treadmill test, Coronary Angiogram +/- transluminal coronary angioplasty) 
were recorded. 
The participants were followed up through mobile phone at one month and six months 
of the date of admission. They were questioned were questioned for cardiac or non-
cardiac events, thromboembolic phenomenon, reinfarction, glycaemic control, blood 
pressure, exercise and dietary habits. 
5.15Data analysis and statistical methods 
 
Data entry was done by the principal investigator from the CRF to in Epidata 
version3.1. This data was then exported to SPSS for windows version 17, IBM 
Corporation. All statistical analysis was done by Dr. Visalakshi Jeyaseelan, 
Department of Biostatistics, Christian Medical College, and Vellore. 
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All baseline data that were categorical were described using numbers and percentages. 
Continuous data were described using mean and standard deviation. For analytical 
statistics student’s t-test, chi-square and other tests were used as appropriate. The 
incidence and incidence density of mortality were reported. Logistic regression 
analysis was performed to determine factors that could independently predict 
mortality in this cohort. All risk ratios are presented with 95% confidence intervals 
and a p value of < 0.05 was taken as significant. 
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6.Results  
6.1Consort figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of individuals included in the study - 140 
STEMI - 8 
Reason for exclusion: 
Consent not given: 4 
Admitted in private medical wards: 2 
Out of area: 3 
 
 
Non-STEMI/UA - 132 
Follow up – 7 
Mortality – 0 
Follow up - 8 
Mortality - 0 
Diagnosis  
Discharge follow 
up 
One Month follow 
up 
Follow up – 119 
Mortality – 15 
Follow up – 132 
Mortality – 12 
Follow up – 0 
Mortality – 0 
Follow up – 62 
Mortality – 11 
Six Month follow 
up 
Number of In Patients in CMC between March 2016 – July 2017: 1,56,866 
No. of Inpatients in general medical wards with Acute Coronary Syndrome - 353 
No. of individuals in our study diagnosed to have Acute Coronary Syndrome- 149 
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Totally we had 19 participants who were lost to follow up, 9 at one month and 10 at 
six-month follow up. At the time of analysis, 47 participants had not completed the 
six-month follow up. 
6.2Baseline Characteristics 
This is a prospective cohort study conducted over a period of 20 months (March 2016 
to July 2017) in a tertiary care teaching hospital in South India. 
Table 1 Baseline Characteristics 
 Total  STEMI Non-STEMI/ UA 
Age (Mean ± SD) 63.5 ± 12.15 63.88 ± 13.84 63.6 ± 11.8 
Sex, Male 74 (53.2%) 6 (75%) 68 (51.9%) 
Source of admission, 
A&E Department 
134 (95.7%) 8 (100%) 126 (95.5%) 
Region     
</=30 Km 75 (53.6%) 4 (50%) 71 (53.8%) 
Duration of 
hospitalisation 
Mean ± SD, Min-Max 
8.50 ± 5.35, 
2 - 40 
8.63 ± 4.44, 
3-14 
8.49 ± 5.4, 
2 - 40 
ICU stay 23 (16.4%) 1 (12.54%) 22 (16.7%) 
Diagnosis  140 (100%) 8 (5.7%) 132 (94.3%) 
In hospital MI 18 (12.9%) 2 (25%) 16 (12.1%) 
Married  138(98.6%) 8 (100%) 130 (98.5%) 
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149 patients were diagnosed to have Acute Coronary Syndrome, 140 fulfilled the 
eligibility criteria and were included in the analysis. The reason for exclusion was 4 
were not willing to be part of the study, 2 were in private wards and 3 were out of 30 
Km hospital radius and were not willing for follow up. The source of admission was 
predominantly Accident and Emergency department in 95.7% patients, all the patients 
with STEMI and 95.5% of the of Non-STEMI/ Unstable Angina. 
6
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Figure 1 Acute Coronary Syndrome - Diagnosis 
 
The study cohort comprised of 140 patients. The age (mean ± SD) of our study cohort 
was 63.5 ± 12.15 years. The diagnosis was STEMI in 8 (5.7%) while in 132 (94.3%) it 
was Non-STEMI/UA. In Hospital Acute Coronary Syndrome occurred 12.9% 
individuals, 25% in STEMI and 12.1% in Non-STEMI/UA respectively.  
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The mean duration of hospitalisation was 8.50 ± 5.35 days. The mean duration of 
hospitalisation among STEMI and Non-STEMI/UA was 8.63 ± 4.44 days and 8.49 ± 
5.4 days respectively. 16.4% individuals required Intensive Care Unit admission, 
16.7% among the Non-STEMI/UA. There was Men predominance, 53.2% 
participants were Men, 75% in the STEMI and 51.9% in the Non-STEMI/UA 
respectively. 
 
 
Figure 2 Residence- Radius from the hospital 
 
53.6 % individuals were from within 30km radius of the hospital, 50% of the STEMI 
and 53.8% of the Non-STEMI/ Unstable Angina while the remaining were from more 
than 30Km away from the hospital radius. 98.6% participants were married. 
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6.3Education 
Table 2 Education 
Education  
Total STEMI 
Non STEMI/ 
Unstable angina 
Illiterate 37 (26.4%) 3 (37.5%) 34 (25.8%) 
Primary school 33 (23.6%) 2 (25%) 31 (23.5%) 
Middle school 30 (21.4%) 0 30 (22.7%) 
High school 21 (15%) 1 (12.5%) 20 (15.2%) 
Graduate 11 (7.9%) 2 (25%) 9 (6.8%) 
Honours/profession 8 (5.7%) 0 8 (6.1%) 
 
26.4% of the individuals were illiterate, 37.5% among STEMI and 25.8% among Non-
STEMI/UA respectively. Only 23.6% had a primary school education. Among the 
STEMI 37.5% were illiterate, 25.0% had primary school education, 12.5% High 
school education while 25.0% were graduates. 
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Figure 3 Education of cohort 
 
Among the Non STEMI 25.8% were illiterate, 23.5% had primary school education, 
22.7% middle school education, 15.2% had High school education, 6.8% were 
graduates while 6.1% had honours or professions. 
6.4Socioeconomic status 
 
Socioeconomic status was calculated by using Modified Kuppuswamy scale- 2012 
(Annexure 13.6). Low socioeconomic status was seen in 20.1% individuals. Majority 
of the individuals 63.3%, were in the lower/ upper lower socioeconomic score, 50.0% 
among STEMI and 64.1% among Non-STEMI/ Unstable Angina. Only 2.9% 
individuals were in the Upper middle scale. 
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Table 3 Socioeconomic Status 
Socioeconomic 
score (Modified 
Kuppuswamy Scale 
2012) 
Total STEMI Non STEMI/ UA 
<5 = (Low) 28 (20.1%) 1 (12.5%) 27 (20.6%) 
5-10 (Lower/ Upper 
lower) 
88 (63.3%) 4 (50%) 84 (64.1%) 
11-15 
(Middle/Lower 
middle_ 
19 (13.7%) 3 (37.5%) 16 (12.2%) 
16-25 (Upper 
middle) 
4 (2.9%) 0 4 (3.1%) 
26-29 Upper 0 0 0 
 
6.5Symptomatology  
 
Figure 4 Symptomatology at presentation 
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The most common presenting complaint was Dyspnoea (94.2%), 62.5% among 
STEMI and 96.2% among Non STEMI/ Unstable angina respectively. 45.7% 
individuals had Chest pain at presentation, 75.0% among STEMI and 43.9% Non 
STEMI/ Unstable angina respectively. 
Table 4 Symptomatology at presentation 
Clinical presentation Total STEMI Non-STEMI/UA 
Onset of symptoms to 
Primary care- Hours 
(Mean, SD, Min-Max) 
29.14 ± 34.6, 
1-168 
18.38 ± 15,  
1- 48 
29.8 ± 35.37,  
1-168 
</= 4 hours 37 (26.4%) 1 (12.5%) 36 (27.3%) 
4-12 22 (15.7%) 2 (25%) 20 (15.2%) 
12-24 5 (3.6%) 1 (12.5%) 4 (3%) 
24-48 37 (26.4%) 3 (37.5%) 34 (25.8%) 
>/=48 39 (27.9%) 1 (12.5%) 38 (28.8%) 
Chest pain 64 (45.7%) 6 (75%) 58 (43.9%) 
Dyspnoea  131 (94.2%) 5 (62.5%) 126 (96.2%) 
Sweating  88 (64.2%) 5 (62.5%) 83 (64.3%) 
Vomiting  11 (7.8%) 0 11 (8.3%) 
Cough  37 (26.4%) 1 (12.5%) 36 (27.3%) 
Fever  30 (21.4%) 1 (12.5%) 29 (21.9%) 
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The mean duration of onset of symptoms to primary care was 29.14 ± 34.6 hours. It 
was 18.38 ± 15 for STEMI as compared to 29.8 ± 35.37 in Non-STEMI/ UA. Only 
26.4% individuals had presented to primary care within 4 hours of onset of symptoms. 
A large sub group of individuals (27.9%) had presented beyond 48 hours of onset of 
symptoms. 
64.2% individuals had sweating, 62.5% among the STEMI and 64.3% among Non 
STEMI/ Unstable angina respectively. Among STEMI, 12.5% had fever, 12.5% had 
cough.  Among Non STEMI/ UA 21.9% had fever, 27.3% had cough, 8.3% had 
vomiting. 
6.6Comorbidities 
 
Figure 5 Common Comorbidities 
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68.6% individuals had Diabetes Mellitus, 25% among STEMI and 71.2% among Non 
STEMI/ Unstable angina respectively.  67.1 % individuals had Hypertension, 50% 
among STEMI and 68.2% among Non STEMI/ Unstable angina respectively. 
Table 5 Comorbidities 
Comorbidities 
Total STEMI 
Non STEMI/ 
Unstable angina 
Diabetes mellitus 96 (68.6%) 2 (25%) 94 (71.2%) 
Hypertension  94 (67.1%) 4 (50%) 90 (68.2%) 
Dyslipidaemia  44 (31.4%) 1 (12.5%) 43 (32.6%) 
Previous ACS 41 (29.3%) 0 41(31.1%) 
Chronic Kidney 
Disease 
19 (13.6%) 0 
19 (14.4%) 
Dialysis 0 0 0 
COPD 22 (15.7%) 0 22 (16.7%) 
Hypothyroidism 9 (6.4%) 1 (12.5%) 8 (6.1%) 
Cerebrovascular 
Accident 
6 (4.3%) 
2 (25%) 4 (3.0%) 
 
31.4% individuals had Dyslipidaemia, 12.5%among STEMI and 32.6% among Non- 
STEMI/UA respectively. 13.6% % individuals had chronic kidney disease, none 
among STEMI while 14.4% among Non-STEMI/UA. None of the individuals were on 
haemodialysis. 15.7% had Chronic Obstructive Pulmonary Disease, none among 
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STEMI and 16.7% among Non-STEMI/UA. 4.3% individuals had prior Cerebro-
Vascular Accident. 29.3% individuals had a prior acute coronary syndrome, none 
among STEMI while 31.1% among Non STEMI/UA.  
6.7Risk Factors 
 
Table 6 Risk Factors 
 
Total STEMI 
Non STEMI/ 
Unstable angina 
Ethanol 
consumption 
27 (19.3%) 
2 (25.0%) 25 (18.9%) 
Smoking  39 (27.9%) 2 (25.0%) 37 (28.0%) 
Tobacco chewing 9 (6.4%) 0 9 (6.8%) 
Non - Veg 131(93.6%) 7 (87.5%) 124 (93.9%) 
 
19.3% individuals were ethanol consumers, 25.0% and 18.9% among STEMI and Non 
STEMI/UA respectively. 27.9% individuals were smokers, 25% and 28% among 
STEMI and Non-STEMI/ Unstable angina respectively. 6.4% individuals were 
tobacco product chewers. 
Physical Activity: 
The International Physical Activity Questionnaires Short (IPAQ) was used to assess 
the physical activity in the study participants. 18.6% individuals were inactive 2.5% 
and 18.9% among STEMI and Non STEMI / UA respectively. 77.9% individuals were 
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minimally active, 87.5% and 77.3% among STEMI and Non STEMI/ UA 
respectively.              
Table 7 International Physical Activity Questionnaires Short (IPAQ) 
IPAQ score Total  STEMI Non-STEMI /UA 
Inactive  26 (18.6%) 1 (12.5%) 25 (18.9%) 
Minimally active 109 (77.9%) 7 (87.5%) 102 (77.3%) 
Hepa active 5 (3.6%) 0 5 (3.8%) 
 
OIL CONSUMPTION: 
Table 8 Cooking oil 
Oil consumption/ 
month 
Total  STEMI Non STEMI 
/Unstable Angina 
<500 2 (1.4%) 0 2 (1.5%) 
500-750 63 (45%)_ 5 (62.5%) 58 (43.9%) 
750-1000 45 (32.1%) 2 (25%) 43 (32.6%) 
1000-1250 21 (15%) 1 (12.5%) 20 (15.2%) 
>=1250 9 (6.4%) 0 9 (6.8%) 
Type of oil    
Soybean oil 8 (5.8%) 1 (12.5%) 7 (5.3%) 
Safflower oil 17 (12.2%) 1 (12.5%) 16 (12.2%) 
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Coconut oil 12 (8.6%) 0 12 (9.2%) 
Sunflower oil 96 (69.1%) 6 (75%) 90 (68.7%) 
 
The average per month oil consumption per person was 500-750 ml in 45% 
participants, 62.5% and 43.9% among STEMI and Non-STEMI/UA respectively. 
 
Figure 6 Type of Cooking Oil consumed 
 
The most common oil used for cooking was Sunflower oil (69.1%). The other oils 
used for cooking were Safflower oil (12.2%) and Coconut oil (8.6%). 
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6.8Examination 
Table 9 Examination 
Parameters  Total STEMI Non-STEMI/UA 
Pulse Rate 
(Mean ±, Min - Max) 
109.81 ± 22.57, 
74 - 240 
105.5 ± 23.42, 
74-142 
110.08 ± 22.58,  
74-24 
Systolic Blood Pressure 
(Mean, SD, Min - Max) 
137.2 ± 47.37, 
0 - 300 
132 ± 36.46,  
86-200 
 137.52 ± 48.04,  
0 - 300 
Diastolic Blood Pressure 
(Mean, SD, Min - Max) 
80.46 ± 28.14, 
0 - 190 
91.25 ± 26.42, 
60 - 140 
79.80 ± 28.21, 
0 - 190 
Respiratory Rate 32.22 ± 8.82,  
16-50 
27.5 ± 9.12,  
20-46 
32.51 ± 8.76, 
16-50 
Oxygen requirement  82 (58.6%) 3 (37.5%)  79 (59.8%) 
Respiratory support 52 (37.1%) 4 (50%) 48 (36.4%) 
Mechanical ventilation 10 (12.5%) 1 (25%) 9 (18.7%) 
Non- Invasive 
Ventilation 
42 (87.5%) 
3 (75%) 39 (81.2%) 
Killips Class    
1 10 (7.1%) 2 (25%) 8 (6.1%) 
2 36 (25.7%) 3 (37.5%) 33 (25%) 
3 72 (51.4%) 2 (25%) 70 (53%) 
4 22 (15.7%) 1 (12.5%) 21 (15.9%) 
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The mean Pulse Rate was 109.81 ± 22.57/minute, 105.5 ± 23.42/minute among 
STEMI while 110.08 ± 22.58 among Non-STEMI/UA. The mean systolic blood 
pressure was 137.2 ± 47.37 mmHg, while the mean diastolic blood pressure was 80.46 
± 28.14 mmHg. The mean respiratory rate was 32.22 ± 8.82/ minute. 
 
Figure 7 Respiratory Suppport 
 
37.1% individuals required respiratory support, 50% and 36.4% among STEMI and 
Non-STEMI/UA respectively. 87.5% individuals required Non-invasive ventilation, 
75% and 81.2% among STEMI and Non-STEMI/UA respectively. 
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Body Mass Index 
Table 10 Body Mass Index 
BMI Total STEMI Non-STEMI/UA 
Assessed, Yes 132 (94.3%) 7 (87.5%) 125 (94.7%) 
<16.00  
(severe thinness) 
3 (2.3%) 0 3 (2.4%) 
16-16.99 (Moderate 
thinness) 
1 (0.8%) 0 1 (0.8%) 
17-18.49 (Mild 
thinness) 
4 (3%) 0 4 (3.2%) 
18.5-24.99 (Normal) 72 (54.5%) 6 (85.7%) 66 (52.8%) 
25-29.99(Pre-obese) 38 (28.8%) 1 (14.3%) 37 (29.6%) 
30-34.99 (Obese 
Class I) 
12 (9.1%) 0 12 (9.6%) 
35-39.99 (Obese 
Class II) 
2 (1.5%) 0 2 (1.6%) 
 
Body Mass Index was assessed for 94.3% participants, 87.5% among STEMI and 
94.7% among Non-STEMI/UA respectively. 
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Figure 8 Body Mass Index 
 
54.5% individuals had Body Mass Index in the normal range, 85.7% among STEMI 
and 52.8% among Non-STEMI/UA respectively. 28.8% individuals were pre-obese. 
10.6% individuals were obese, none among STEMI while 11.2% among Non-
STEMI/UA respectively. 
Killips Class 
Table 11 Killips Class 
Killips Class Total STEMI Non-STEMI/UA 
1 10 (7.1%) 2 (25.0%) 8 (6.1%) 
2 36 (25.7%) 3 (37.5%) 33 (25%) 
3 72 (51.4%) 2 (25%) 70 (53%) 
4 22 (15.7%) 1 (12.5%) 21 (15.9%) 
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51.4% individuals were in Killips class 3, 25% among STEMI and 53% among 
Non-STEMI/UA respectively. Killips class was 4 in 15.7% individuals, 12.5% 
among STEMI while 15.9% among Non-STEMI/UA respectively. 
TIMI score 
Table 12 TIMI Score 
TIMI STEMI Non-STEMI/UA 
1 0 0 
2 0 7 (5.3%) 
3 4 (50%) 55 (42%) 
4 2 (25%) 38 (29%) 
5 1 (12.5%) 29 (22.1%) 
6 0 2 (1.5%) 
8 1 (12.5%) 0 
 
The commonest TIMI score was 3 in 42% of Non-STEMI/UA, 29% had TIMI score 
of 4. The commonest TIMI score was 3 in 50% of STEMI, 25 % had TIMI score of 4.  
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6.9Investigations 
 
Table 13 Investigation 
 
 Total STEMI Non-STEMI/UA 
Hemoglobin 
Mean, SD, Min- 
Max 
11.4 ± 2.36, 
5.7-16.9 
12.45 ± 2.13, 
9-14.9 
11.37 ± 2.37,  
5.7-16.9 
HBA1C, Yes 125 (89.3%) 7 (87.5%) 118 (89.4%) 
< 5.7 16 (12.8%) 3 (42.9%) 13 (11%) 
5.7-6.4 31 (24.8%) 1 (14.3%) 30 (25.4%) 
>6.5 78 (62.4%) 3 (42.9%) 75 (63.6%) 
Creatinine 1.82 ± 1.35 
0.5-7.13 
1.82 ± 1.75,  
.97-6.10 
1.83 ± 1.33 
5-7.13 
Lipid Profile, Yes 110 (78.6%) 8 (100%) 102 (77.3%) 
LDL    
<60 27 (24.5%) 3 (37.5%) 24 (23.5%) 
60-130 69 (62.7%) 4 (50%) 65 (63.7%) 
130-159 11 (10%) 0 11 (10.8%) 
High risk 3 (2.7%) 1 (12.5%) 2 (2%) 
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The mean haemoglobin was 11.4 ± 2.36 gm/dl. The mean creatinine was 1.82 ± 
1.35mg/dl. HBA1C was done for 89.3% individuals.12.8% individuals had HBA1C 
less than 5.7, 42.9% among STEMI while 11% among the Non-STEMI/UA. 62.4% 
participants had HBA1C of more than 6.5, 42.9% among STEMI and 63.6% among 
Non-STEMI/UA respectively.  
ECG 
Table 14 ECG 
ECG Total  STEMI Non-STEMI/UA 
Anterior wall 33 (23.6%) 2 (25.0%) 31 (23.5%) 
lateral 53 (37.9%) 3 (37.5%) 50 (37.9%) 
Septum  3 (2.1%) 0 3 (2.3%) 
Anteroseptal 37 (26.4%) 2 (25.0%) 35 (26.5%) 
Inferior wall 27 (19.3%) 3 (37.5%) 24 (18.2%) 
Arrhythmia  2 (1.4%) 0 2 (1.5%) 
 
The commonest site involved as seen in ECG was lateral wall in 37.9% participants, 
37.5% and 37.9% among STEMI and Non-STEMI/UA respectively. Anterior wall 
was involved in 23.6%, Anteroseptal in 26.4% while 19.3% had inferior wall 
involvement. 
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Chest X Ray 
Table 15 Chest X-Ray 
Chest X RAY Total  STEMI Non-STEMI/UA 
Pulmonary edema 79 (56.4%) 3 (37.5%) 76 (57.6%) 
Pleural effusion 7 (5%) 0 7 (5.3%) 
Cardiomegaly  102 (72.9%) 4 (50%) 98 (74.2%) 
 
The commonest Chest X-Ray finding was Cardiomegaly (72.9%), 50% and 74.2% 
among STEMI and Non STEMI/UA respectively. Chest X RAY showed Pulmonary 
oedema in 56.4%, 37.5% and 57.6% among STEMI and Non STEMI/UA 
respectively. 
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ECHO 
Table 16 ECHO 
ECHO Total  STEMI Non-
STEMI/UA 
Yes  116 (82.9%) 8 (100%) 108 (81.8%) 
RWMA 82 (70.7%) 8 (100%) 74 (68.5%) 
Diastolic dysfunction 15 (12.9%) 2 (25.0%) 13 (12%) 
Ejection fraction     
Normal :>/=55 31 (26.7%) 0 31 (28.7%) 
Mild: 45-54 21 (18.1%) 3 (37.5%) 18 (16.7%) 
Moderate: 30-44 54 (46.5%) 4 (50%) 50 (16.3) 
Severe :</=30 10 (8.6%) 1 (12.5%) 9 (8.3%) 
 
Transthoracic ECHO was done in 82.9% participants. It showed regional wall motion 
abnormality in 70.7% participants, 100% and 68.5% among STEMI and Non-
STEMI/UA respectively. Mild LV systolic dysfunction was seen in 37.5% among the 
STEMI while 6.7% among Non-STEMI/UA. Severe LV Dysfunction was seen in 
8.6% participants, 12.5% among STEMI and 8.3% among Non-STEMI/UA. 
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Cardiac Enzymes 
Table 17 Cardiac Enzymes 
Cardiac Enzymes Total  STEMI Non-STEMI/UA 
At Admission     
Troponin T 122 (87.1%) 5 (62.5%) 117 (88.6%) 
Troponin I 17 (12.1%) 2 (25%) 15 (11.4%) 
CK MB 93 (66.4%) 3 (37.5%) 90 (68.2%) 
At 6 hours    
Troponin T 119 (85.6%) 4 (50%) 115 (87.8%) 
Troponin I 17 (12.1%) 2 (25%) 15 (11.4%) 
CK MB 107 (77%) 4 (57.1%) 103 (78%) 
 
At admission, Cardiac enzymes Troponin T was done for 87.1% participants, 62.5% 
and 88.6% among the STEMI and Non-STEMI/UA respectively. Due to non-
availability reagent needed for Troponin T test during a brief period, 12.1% 
participants had Troponin I done, 25% among STEMI while 11.4% among Non-
STEMI/UA. of At-admission, CK-MB was done for 66.4% participants, 37.5% and 
68.2% among the STEMI and Non-STEMI/UA respectively. At 6 hours repeat cardiac 
Troponin T was done for 85.6%, Troponin I in 12.1% while CK-MB was done in 77% 
participants. 
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6.10Outcome 
6.10.1Primary Outcome 
6.10.1.1Mortality and Morbidity at Discharge 
 
Table 18 Mortality and Morbidity at Discharge 
 Total  STEMI NSTEMI/UA  
Death 12 (8.6%)  12 (9.1%) 
Cardiac cause 6 (50%) 0 6 (50%) 
Non-Cardiac cause 6 (50%) 0 6 (50%) 
Reinfarction 3 (2.1%) 0 3 (2.3%) 
Cardioembolic 
phenomenon 
0 
0 
0 
Cardiac arrest 
(resuscitated) 
0 0 0 
Optimal Blood Pressure 124 (88.6%) 8 (100%) 116 (87.9%) 
Optimal Glycemic control 135 (96.4%) 8 (100%) 127 (96.2%) 
 
The in-hospital mortality was 8.6%, 9.1% among the Non-STEMI/UA. In the Non-
STEMI/UA group, the cause mortality was cardiac in 50% while non-cardiac in 50%. 
Reinfarction was seen in 2.3% among the Non-STEMI/UA. Optimal Blood pressure 
was seen in 88.6% individuals, 100% and 87.9% among STEMI and Non STEMI/UA 
respectively. Glycaemic control was optimal in 96.4%, 100% and 96.2% among 
STEMI and Non STEMI/UA respectively. 
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6.10.1.2Mortality and Morbidity at One-Month  
 
Table 19 Mortality and Morbidity at One-Month 
One Month Outcome Total  STEMI NSTEMI/ UA 
No. followed up 119 (93.0%) 7 (87.5%) 112 (93.3%) 
Death 15 (12.6%) 0 15 (13.4%) 
Cardiac cause 10 (66.7%) 0 10 (66.7%) 
Non-Cardiac cause 5 (33.3%) 0 5 (33.3%) 
Reinfarction 9 (7.6%) 0 9 (8%) 
Thromboembolic 
phenomenon 
2 (1.7%) 0 2 (1.8%) 
Blood pressure 105 (88.2%) 7 (100%) 98 (87.5%) 
Glycemic control 98 (82.4%) 7 (100%) 91 (81.2%) 
Daily walk 105 (88.2%) 7 (100%) 98 (87.5%) 
 
One month follow up was completed for 93.0% individuals, 87.5% and 93.3% among 
STEMI and Non-STEMI/UA respectively. One-month mortality was 12.6% at one 
month, 0% and 13.4% among STEMI and Non-STEMI/UA respectively. The cause of 
mortality was cardiac in 66.7% individuals while non - cardiac in 33.3% individuals. 
Thromboembolic phenomenon was seen in 1.7% individuals. 88.2% individuals had 
optimal blood pressure, 100% and 81.2% among STEMI and Non-STEMI/UA 
respectively. Glycaemic control was adequate in 82.4% individuals, 100% and 87.5% 
among STEMI and Non STEMI/UA respectively. 
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6.10.1.3Mortality and Morbidity at Six-Month  
 
Table 20 Mortality and Morbidity at Six-month 
Six Month Outcome Total  STEMI NSTEMI/ UA 
No. followed up 62 (86.1%) 0 62 (84.9%) 
Death 11 (17.7%) 0 11 (17.7%) 
Cardiac cause 5 (45.5%) 0 5 (45.5%) 
Non-Cardiac cause 6 (54.5%) 0 6 (54.5%) 
Reinfarction 1 (1.6%) 0 1 (1.6%) 
Thromboembolic 
phenomenon 
0 
0 0 
Optimal Blood pressure 55 (88.7%) 0 55 (88.7%) 
Optimal Glycemic 
control 
55 (88.7%) 0 
55 (88.7%) 
Daily walk 58 (93.5%) 0 58 (93.5%) 
 
86.1% individuals were followed up at six-month, nil among STEMI and 84.9% 
among Non-STEMI/UA. Six-month mortality was 17.7% among Non-STEMI/UA.  
respectively. The cause of mortality was cardiac in 45.5% individuals while non-
cardiac in 54.5% individuals among the Non - STEMI/UA. Optimal blood pressure 
and glycaemic control was seen in 88.7% individuals among Non-STEMI/UA 
respectively. 
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6.11Secondary outcome 
 
6.11.1Risk factors affecting the mortality at one month 
 
Table 21Risk factors affecting mortality at One-Month 
 Dead  Alive  Odds ratio, P value 
Age (Mean±SD) 66.93 ± 10.09 62.44 ± 12.26  
Sex, Male  6 (40%) 56 (53.8%) .57 (0.19-1.72), 0.41  
Diabetes Mellitus 8 (53.3%) 75 (72.1%) .44 (.15 – 1.33), .147 
Hypertension 12 (80%) 103 (99%) .039 (.004 – .403), .006 
Prior Acute Coronary 
Syndrome 
4 (26.7%) 30 (28.8%) 
.89 (.26- 3.04),1 
Smoking 5 (33.3%) 24 (23.1%) 1.67 (.52- 5.35), .52 
Chronic Kidney 
Disease 
2 (13.3%) 16 (15.4%) 
.85 (.17 - 4.11) ,1 
Ethanol  3 (20%) 19 (18.3%) 1.12 (.29 - 4.35), 1 
 
In our study cohort majority of the individuals were eligible for one month follow up 
while significant less individuals were eligible for six-month follow up. Among the 
individuals who had mortality at one month, the mean age was higher (66.93 ± 10.09 
years) as compared to individuals who were alive (62.44 ± 12.26). At one month, 
individuals who were smoking and were ethanol consumers had lower odds of being 
alive. 
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Figure 9 TIMI Score versus Mortality at One-Month 
 
TIMI Score  Dead Alive TIMI Prediction 
0/1 0 0 4.7% 
2 6 (50%) 6 (50%) 8.3% 
3 5 (9.6%) 47 (90.4%) 13.2% 
4 4 (12.5%) 28 (87.5%) 19.9% 
5 5 (19.2%) 21(80.8%) 26.6% 
6/7 0 2 (100%) 4.9% 
 
The mortality at one month was compared with the TIMI score, 50% mortality at one 
month was seen in individuals with TIMI score of 2, while 9.6%, 12.5% and 19.2% 
mortality in individuals with TIMI score 3, 4 and 5 respectively.  
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Figure 10Multivariate Analysis: Mortality at One-Month versus Risk Factor 
 
Factor Beta 
coefficient 
Odds Ratio Confidence 
Interval 
P Value 
Age  .036 1.036 .988-1.091 .171 
Sex, Male  -0.560 0.571 .190-1.721 .320 
Diabetes Mellitus 
(Optimal) 
-0.817 .442 .147-1.329 .146 
Hypertension 
(Optimal) 
.333 1.395 .414-4.699 .591 
Prior Acute 
Coronary 
Syndrome 
-.109 .897 .265-3.040 .861 
Smoking .511 1.667 .519-5.351 .391 
Chronic Kidney 
Disease 
-.167 .846 .174-4.113 .836 
Alcohol .112 1.118 .287-4.355 .872 
 
A multivariate analysis was done on factors that were significant on univariate 
analysis. There was a trend towards reduced mortality at one month for those with 
well controlled diabetes as compared to poorly controlled diabetes. None of the other 
risk factors were found to be significant. 
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6.11.2Socioeconomic Status and Mortality at One-month and Six-month 
 
Table 22 Socioeconomic Status and Mortality at One and Six month 
Socioeconomic 
Status 
Dead Alive 
 One-Month Six-Month One-Month Six-Month 
<5(Lower) 6 (26.1%) 2 (15.4%) 17 (73.9%) 11 (21.6%) 
5-10(Upper Lower) 7 (9.3%) 6 (15%) 68 (90.66%) 34 (85%) 
11-15(Lower 
Middle) 
2 (12.5%) 1 (20%) 14 (87.5%) 4 (80%) 
16-25(Upper Middle) 0 1 (33.3%) 4 (3.9%) 2 (66.7%) 
 
In our study cohort, a large proportion of cohort were in upper lower socioeconomic 
scale. On assessing the socioeconomic status with the outcome, at one-month 
mortality was 26.1% in participants of lower socioeconomic status while at six-month 
the mortality was 15.4%.  
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6.11.3Kaplan Meier Survival Estimate 
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Figure 11 Kaplan Meier Survival Estimate 
 
A Kaplan Meier survival curve was made for our study, the uncensored data showed 
that 103 survived at 30 days while 54 survived at 180 days. As seen in the curve, most 
deaths occur early within the first one month and remain stable after three months. 
However most patients in general medical have multiple comorbidities. 
Approximately 50% of the early deaths were due to non-cardiac causes.   
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6.12Other Results 
 
6.12.1In hospital management 
 
Table 23 In Hospital Management 
In hospital management  Total STEMI Non-
STEMI/UA 
Time of hospitalisation to 
appropriate intervention -Hours 
(Mean, SD, Min-Max) 
1.77 ± 1.82, 
0.40 -12  
2.06 ± 2.86, 
0.5- 8 
1.75 ± 1.75, 
0.4 -12 
Antiplatelet drugs 140 (100%) 8 (100%) 132 (100%) 
Aspirin 140 (100%) 8 (100%) 132 (100%) 
Clopidogrel  137 (97.9%) 8 (100%) 129 (97.7%) 
Antianginals 120 (85.7%) 7 (87.5%) 113 (85.6%) 
Lipid-lowering drugs 140 (100%) 8 (100%) 132 (100%) 
Antihypertensive medications 135 (96.4%) 8 (100%) 127 (96.2%) 
β blockers 103 (76.3%) 8 (100%) 95 (74.8%) 
ACE inhibitors  60 (44.4%) 6 (75%) 54 (42.5%) 
ARB 9 (6.7%) 1 (12.5%) 8 (6.3%) 
Diuretics  114 (84.4%) 6 (75%) 108 (85%) 
Anti-diabetic medications 100 (71.4%) 3 (37.5%) 97 (73.5%) 
Oral  37 (37%) 3 (100%) 34 (35.1%) 
Biguanides  36 (97.3%) 3 (100%) 33 (97.1%) 
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Sulphonylureas 9 (24.3%) 1 (33.3%) 8 (23.5%) 
Parenteral  83 (83%) 2 (66.7%) 81 (83.5%) 
Bolus regimen 76 (91.6%) 2 (100%) 74 (91.4%) 
Split mixed regimen 5 (6.2%) 0 5 (6.3%) 
Thrombolysis  2 (1.4%) 2 (25%) 0 
Anticoagulation 138 (98.6%) 8 (100%) 130 (98.5%) 
Heparin  69 (49.6%) 2 (25%) 67 (51.1%) 
LMWH 69 (49.6%) 6 (75%) 63 (48.1%) 
Inotropes  25 (17.9%) 2 (25%) 23 (17.4%) 
Cardiology consult 104 (74.3%) 8 (100%)  96 (72.7%) 
Medical management 86 (82.7%) 6 (75%) 80 (83.3%) 
Advised Coronary Angiogram 18 (17.3%) 2 (25%) 16 (16.7%) 
 
Double Antiplatelet was given to 97.7% individuals, 100% and 97.7% among STEMI 
and Non-STEMI/UA respectively.  Cyclooxygenase inhibitors was given to all the 
individuals. 97.9% individuals received ADP receptor inhibitors, 100% and 97.7% 
among STEMI and Non STEMI respectively. Statins was given to all the individuals 
(100%) in both the groups.  
96.4 % were given antihypertensive medications, 100% and 96.2% among STEMI and 
Non-STEMI/UA respectively. The most common antihypertensive medication was 
beta blocker (76.3%), 100% and 74.8%) among STEMI and Non-STEMIUA 
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respectively. 44.4% individuals were given ACE inhibitors, 75% and 42.5% among 
STEMI and Non-STEMI/UA respectively. 84.4% individuals were on diuretics, 75% 
and 85% among STEMI and Non-STEMI/UA respectively. 
 
Figure 12 In-Hospital Medications 
 
71.4%% were given antidiabetic medications, 37.5% and 73.5% among STEMI and 
Non-STEMI/UA respectively. Biguanide (97.3%) was the most common antidiabetic 
medication given 100% and 97.1% among STEMI and Non-STEMI/UA respectively. 
Parenteral therapeutic agents were given to 83% individuals, 66.7% and 83.5% among 
STEMI and Non-STEMI/UA respectively. The most common parenteral regimen used 
was Bolus insulin regimen (91.6%), 100% and 91.4% among STEMI and Non-
STEMI/UA respectively. 
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98.6% individuals received Anticoagulation, 100% of STEMI and 98.5% of Non-
STEMI/UA. Heparin and Low molecular weight heparin was used equally. 51.1% of 
the Non-STEMI/ UA received Heparin.  Inotropes was required in 17.9% individuals, 
25% of STEMI and 17.4% of Non-STEMI/UA respectively. 74.3% individuals were 
seen by cardiologist, 100% of STEMI and 72.7% of Non-STEMI/UA respectively.  
Coronary Angiogram was advised to 17.3% individuals, 25% and 16.7% among 
STEMI and Non-STEMI/UA respectively.  
6.12.2Discharge Advice 
Table 24 Discharge Advice 
Discharge Advice Total  STEMI NSTEMI 
Antiplatelet drugs 128 (100%) 8 (100%) 120 (100%) 
Aspirin  128 (100%) 8 (100%) 120 (100%) 
Clopidogrel  121 (94.5%) 8 (100%) 113 (94.2%) 
Lipid-lowering drugs 128 (100%) 8 (100%) 120 (100%) 
Antianginal drugs 107 (83.6%) 7 (87.5%) 100 (83.3%) 
Antihypertensive 
medications 
127 (99.2%) 
8 (100%) 119 (99.2%) 
β blockers 116 (91.3%) 8 (100%) 108 (90.8%) 
ACE inhibitors  55 (43.3%) 6 (75%) 49 (41.2%) 
ARB 16 (12.6%) 1 (12.5%) 15 (12.6%) 
Diuretics  92 (73.0%) 5 (62.5%) 87 (73.7%) 
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Double Antiplatelet was advised to 94.5% individuals, 100% and 94.2% among 
STEMI and Non-STEMI/UA respectively.  Cyclooxygenase inhibitors was advised to 
all the individuals in both groups. ADP receptor inhibitors was advised to 94.5% 
individuals, 100% and 94.2% among STEMI and Non-STEMI/UA respectively. 
Statins was advised to all the individuals in both groups. 
99.2% % were advised antihypertensive medications, 100% and 99.2% among STEMI 
and Non-STEMI/UA respectively. The most common antihypertensive medication 
was beta blocker (91.3%), 100% and 90.8% among STEMI and Non-STEMI/UA 
respectively. 43.3% individuals were on ACE inhibitors, 75% and 41.2% among 
STEMI and Non-STEMI/UA respectively. Diuretics was advised to 73.0% while 
ARB’s were advised to 12.6% individuals.  
Antidiabetic medications 86 (67.2%) 3 (37.5%) 83 (69.2%) 
Oral  48 (55.8%) 3 (100%) 45 (54.2%) 
Biguanides  41 (85.4%) 3 (100%) 38 (84.4%) 
Sulphonylureas 22 (45.8%) 0 22 (48.9%) 
Parenteral  45 (52.3%) 2 (66.7%) 43 (51.8%) 
Basal  14 (31.8%) 0 14 (33.3%) 
Bolus regimen 12 (27.3%) 1 (50%) 11 (26.2%) 
Split mixed regimen 19 (42.2%) 1 (50%) 18 (41.9%) 
Coronary angiogram 38 (29.7%) 5 (62.5%) 33 (27.5%) 
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Figure 13 Discharge medications 
 
67.2% individuals were advised antidiabetic medications, 37.5 and 69.2% among 
STEMI and Non-STEMI/UA respectively. The most common antidiabetic medication 
was Biguanides (85.4%), 100% and 84.4% among STEMI and Non-STEMI/UA 
respectively. 52.3% individuals were advised parenteral therapeutic agents, 66.7% and 
51.8% among STEMI and Non-STEMI/UA respectively. The most common 
combination regimen used was split mixed regimen (42.2%), 50% and 41.9% among 
STEMI and Non-STEMI/UA respectively.  
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7.Discussion  
 
According to World Health Organization, in 2010 NCDs led to 5.87 million deaths 
globally. In India, there were 1.2 million deaths in men and 0.9 million deaths in 
women due to NCDs.  In India, the age adjusted CVD mortality rates are 349/100,000 
in men and 265/100,000 in women (39) 
According to the National Registry of Myocardial Infarction, there has been decline in 
STEMI and rise in percentage of Non-STEMI. In between 1994 and 2006 the 
proportion of Non STEMI increased from 25.33 % to 59.1 % while the proportion of 
STEMI reduced from 74.6% to 41.03%.  From 1990 to 2006, there was increase in 
mean age from 64.1 to 66.4 years, in males from 61.8 to 63.7 years while in females 
from 69.1 to 71.0 years. The proportion of women increased from 32.4% to 37.0%. 
The in Hospital mortality in 1994 was 10.4% which reduced to 6.3% in 2006, in 
STEMI group it reduced from 11.5% to 8.0% while in Non STEMI it reduced from 
7.1% to 5.2%. (29) 
In the INTERHEART study, the age of age of first acute myocardial infarction was 53 
years median age (46-61 years) in South Asia. In South Asia, 8.9% individuals at 
presentation were less than 40 years of age.  (31) 
According to the Registrar General of India, in 2015 Circulatory diseases contributed 
to 33.2% of medically certified deaths, 32.8 % and 33.9 % among men and women 
respectively. 26.9% deaths were due to Ischemic Heart Diseases (IHD). (42)  
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26.4% individuals were illiterate in our study and only 23.6% had completed primary 
school education.  
In our study the diagnosis was STEMI in 8 (5.7%) while in 132 (94.3%) it was Non-
STEMI/UA.  The age (mean ± SD) of our study cohort was 63.5 ± 12.15 years. Male 
were 53.2%. The mean duration of hospitalisation was 8.50 ± 5.35 days. 16.4% 
individuals required Intensive Care Unit care.  Time of onset of symptoms to 
hospitalisation was less than 4 hours in 26.4% individuals. Time of hospitalisation to 
appropriate intervention was 1.77 ± 1.82(mean) hours. 
In GRACE registry diagnosis was STEMI in 39%, Non-STEMI in 39% and 22% had 
unstable angina. The mean age was 64.9 (12.6). There was male predominance 63% 
(33). In CREATE the diagnosis was STEMI in 60·6% while Non-STEMI in 39.4% 
individuals. The mean age was 57·5 +/-12·10 years. Time to onset of symptoms to 
presentation was less than 4 hours in 38·1% individuals.(59) 
As compared to other Acute Coronary Syndrome registries the proportion of STEMI 
was low in out cohort, the reason for it is probably because STEMI requires PCI 
intervention and most of them are managed by Cardiologist while we had included 
individuals who were admitted in the general medical wards. 
In our study we had calculated the socioeconomic status by using Modified 
Kuppuswamy Scale- 2012. Low socioeconomic status was seen in 20.1% individuals. 
Majority of the individuals 63.3%, were in the lower/ upper lower socioeconomic 
status. Only 2.9% individuals were in the Upper middle scale. 
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In our study, 68.6% individuals had Diabetes Mellitus, 67.1 % had Hypertension, 
31.4% individuals had Dyslipidaemia, 13.6% individuals had chronic kidney disease, 
none of the individuals were on haemodialysis. Prior Acute Coronary Syndrome was 
seen in 29.3% individuals. 19.3% participants were ethanol consumers, 27.9% 
individuals were smokers.  The International Physical Activity Questionnaires Short 
(IPAQ) was used to assess the physical activity in the study participants. A significant 
proportion of the participants (18.6%) were physically inactive. 77.9% participants 
were minimally active. 
In GRACE registry, individuals who were current smokers or history of smoking was 
there in 57% Non-STEMI, Diabetes Mellitus in 27% Non-STEMI, Hypertension in 
59% Non-STEMI. (33) In CREATE Registry, Body Mass Index was 20–24·9 kg/m2, 
among 52·9% participants. 30.4% individuals were known to have diabetes mellitus, 
37.7% had hypertension. 17·5% participants had prior Acute Coronary Syndrome, 
26·6% among the Non-STEMI. 27.9% participants were current smokers. (55) 
Our study participants had higher risk factor burden of Diabetes Mellitus, 
Hypertension, prior Acute Coronary Syndrome as compared to the study participants 
in the CREATE Registry. 
In hospital management, double antiplatelet was given to 97.7% individuals. 
Cyclooxygenase inhibitors (Aspirin) was given to all the individuals. 97.9% 
individuals received ADP receptor inhibitors (Clopidogrel). Statins was given to all 
the individuals (100%).  Beta blocker was given to 76.3% individuals. 44.4% 
individuals were given ACE inhibitors. 84.4% individuals were given diuretics. 
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Nearly 100% of our participants received Heparin. Unfractionated and Low molecular 
weight heparin were used equally. Inotropes was required in 17.9% individuals. 
74.3% individuals were seen by cardiologist, 100% of STEMI and 72.7% of Non-
STEMI/UA respectively. Coronary Angiogram was advised to 17.3% individuals, 
25% and 16.7% among STEMI and Non-STEMI/UA respectively. None had coronary 
angiogram during the hospitalisation. 
In GRACE registry the in-hospital medications use was, Aspirin in 95% and 91% of 
STEMI and Non-STEMI respectively, Ticlopidine/clopidogrel in 37% and 29% of 
STEMI and Non-STEMI respectively, beta blocker is 81% and 78% of STEMI and 
Non-STEMI respectively. Unfractioned heparin in 66% and 61% of STEMI and Non-
STEMI respectively. ACE inhibitors in 66% and 55% of STEMI and Non-STEMI 
respectively, oral or topical nitrates in 58% and 72% of STEMI and Non-STEMI 
respectively. Thrombolysis was done in 47% and 5% of STEMI and Non-STEMI 
respectively. Percutaneous coronary intervention was done in 6% and 13% of STEMI 
and Non-STEMI respectively. (33) 
In the CREATE Registry, in hospital management included double antiplatelet was 
given to 97·9% individuals. Beta blocker was given to 59·3% individuals. 56·8% 
individuals were given ACE inhibitors/ ARB’s. 81·3% individuals received 
Anticoagulation. (59).  
Higher proportion of Beta Blocker and anticoagulation use was seen in our study 
participants as compared to the in-hospital management in CREATE Registry. 
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In our study, Discharge medications advised were, Double Antiplatelet was advised to 
94.5% individuals. Statins was advised to all the individuals. 99.2% % were advised 
antihypertensive medications. The most common antihypertensive medication was 
beta blocker - 91.3%. 43.3% individuals were on ACE inhibitors. ARB’s were advised 
to 12.6% individuals. 73% individuals were advised diuretics.   
In Kerala ACS Registry, discharge medications were, Aspirin and Clopidogrel was 
given to 76.4 %and 79. % participants respectively, beta blockers to 62.7 %, statins to 
70.1%, ACE/ ARBs to 25.5%, nitrates to 75.1 % participants (56). 
As compared to the Kerala ACS Registry which had assessed the discharge 
medications, our study participants received higher proportion of Antiplatelet, beta 
blockers, ACE/ARB’s. 
In-hospital mortality was 8.6% (9.1% among the Non-STEMI/UA). In the Non-
STEMI/UA group, the cause specific mortality was cardiac in 4.5% while non-cardiac 
in 4.5%. Reinfarction was seen in 2.3% among the Non-STEMI/UA.  
In Kerala ACS registry, the unadjusted in hospital mortality rate was 8.2% in STEMI, 
1.8% among Non-STEMI. The  In hospital reinfarction was 0.5% while in hospital 
stroke was 0.3% (56) 
In our study, one month follow up was completed for 93.0% individuals, 87.5% and 
93.3% among STEMI and Non-STEMI/UA respectively. One-month mortality was 
12.6% at one month, 0% and 13.4% among STEMI and Non-STEMI/UA respectively. 
The cause of mortality was cardiac in 66.7% while non-cardiac in 33.3%.  
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In EHS-ACS-II study, the in-hospital mortality and 30-day mortality was 4.0% and 
5.1% respectively. The data for 30 days follow up was available for 85% of hospital 
survivors. The 30-day mortality was 5.1%. (32)  
In GRACE registry, in hospital mortality was seen in 7% and 6% of STEMI and Non- 
STEMI respectively. Reinfarction was seen in 3% and 2% of STEMI and Non-STEMI 
respectively. (33) 
 In CREATE Registry, the 30 day outcome was assessed which showed mortality of 
8·6% among Non-STEMI and 6·7% among STEMI (59). Our one-month mortality 
was higher due to inclusion of non-cardiac mortality. 
86.1% individuals in our study who were eligible for six months follow up were 
followed up.  The Six-month mortality was 17.7% among Non-STEMI/UA. The cause 
of mortality was cardiac in 45.5% while non-cardiac in 54.5% among the Non- 
STEMI/UA.  
On comparing the outcome of our cohort, there was a higher mortality in our cohort as 
compared to National and International Acute Coronary Syndrome Registries. The 
reason for higher mortality in our cohort was considered due to multiple comorbid 
illness, delayed presentation and not unwillingness for cardiac intervention as advised 
by cardiologist.  
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Table 25 Comparison of Outcome of Our study with other studies 
 
 In-Hospital One-Month Six-Month 
 Total Non-
STEMI 
Total Non-
STEMI 
Total Non-
STEMI 
Our Study* 8.6% 9.1% 12.6% 13.4% 17.7% 17.7% 
Kerala ACS 
Registry(56) 
3.9 1.8 NA NA NA NA 
CREATE 
registry(59) 
NA NA 6·7% 4% NA NA 
EHS-ACS 
2(32) 
4.4% 2.5 5.6% 3.4 NA NA 
GRACE 
Registry(38) 
 7.5% 5 NA 3% 12.1% 6 
 
*includes Cardiac and Non-Cardiac mortality. Cardiac mortality was 50% in hospital, 
66.7% at one-month and 45.5% at six-month 
In our study, the participants with well controlled diabetes had a trend towards better 
outcome at six-months. No other risk factor decreased or increased risk independently 
in our study. In GRACE registry odds of mortality due to smoking was 1.84.(33) 
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8.Limitations 
 
The following were the limitations of our study 
1. We were unable to reach our calculated sample size of 213 subjects due to time 
constraints. However, we plan to continue data collection.   
2. The follow up data for six-month was not completed for all participants. This 
again will be completed in a few months.  
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9.Conclusions 
 
Our study was done in general medical wards to assess the long-term mortality in 
individuals admitted with acute coronary syndrome. 
9.1Conclusion of Primary Objective 
 
Among participants admitted to a general medical ward with acute coronary 
syndrome, the mortality at discharge, one month and six months following onset were 
8.6%, 12.6% and 17.7% respectively. Among those who expired, mortality due to 
cardiac cause was 50%, 66.7% and 45.5% at discharge, one-month and six-month 
respectively. 
 
9.2Conclusion of Secondary Objective 
 
9.2.1 Subjects with controlled diabetes had a trend towards better outcome (OR: .442, 
.147-1.329, p= .146) at one month compared to those with poor control.  
9.2.2 On assessing the socioeconomic status with the outcome, there was a trend 
towards higher mortality in participants with lower socioeconomic status. 
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11.2Clinical research form 
 
Name:                                            Hospital Number:                                Serial ID 
number : 
 
Ward/MHDU/ICU                        Medicine Unit:                    Age:                  Sex- 
M/F 
 
DOA:                                             DOD:                                    Duration of 
Hospitalization:   
 
Admission source:  Accident and Emergency/ OPD                     In hospital transfer: 
Y/ N 
 
Address: 
 
Mobile No./ Landline No. -                                                         Duration of ICU stay 
 
Diagnosis:  STEMI NSTEMI UNSTABLE ANGINA 
 
a) Socio-demographic details – Married/ Unmarried 
b) Education status -  
Illiterate Primary school certificate Middle school certificate 
High school  
certificate 
Intermediate or post high school diploma/ 
graduate or post graduate 
Graduate or post graduate 
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Profession or honors   
Type of family -    Nuclear Single parent family Extended family 
 
a)  Occupational details – 
b) Socioeconomic class : Modified Kuppuswamy socioeconomic scale ( Appendix 
) 
I. Clinical Presentation :           
Chest pain  Radiation Onset - Duration NYHA- 
Breathlessness MRC  Duration NYHA- 
Sweating Others- 
     
II. Time of Onset of Symptoms to Primary care/ Hospitalization 
III. Risk Factor details –  
Diabetes Mellitus  Duration Compliance   
Hypertension  Duration  Compliance   
Dyslipidaemia Duration  Compliance   
Previous ACS – Yes/ No No. of episodes - Last episode - Prior use of Aspirin - Yes /  No 
Chronic kidney disease -  Yes /  No Duration Dialysis 
 Alcohol consumption - Yes / No Quantity 
Unemployed Unskilled Semiskilled Skilled 
Cleric or shop owner or 
farmer 
Semi profession Profession  
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Smoking – Yes / No Pack years 
Tobacco chewing – Yes / No Duration ( Years ) - 
Physical activity: IPAQ Score Diet – Veg / Non Veg 
Iodized – Yes /  No  Gram/ day -  
  
IV. Dietary habits :   Food Frequency chart-  
 Never  Once a week <3 times/week >/=3 times/week Daily  Fortnight  
Egg yolk       
Milk ( full fat)       
Red meat 
(Beef, Mutton) 
      
White meat 
(Chicken) 
      
Organ meat 
(Brain,Liver, 
Kidney) 
      
Shell fish (Prawn, 
crab, Lobster) 
      
Butter / Ghee       
Fried Snacks 
(Vadai, Bonda, 
 Puff) 
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V. Oil consumption : 
Soybean oil Safflower oil Coconut oil 
Sunflower oil Cotton seed oil Others 
Quantity per person per day -  
 
VI.  Medication details :  
a) Antihypertensive medications:  
ACE inhibitors ARB’s Beta blockers Others- 
b)  Anti Diabetic Medications :  
Oral Antidiabetic Medications – Yes /  No  Duration -  
Biguanides Sulphonylureas Alpha glucosidase inhibitors 
Thizolidinediones Dipeptidyl Peptidase inhibitors Others - 
Parental Therapeutic agents -  Yes / No Duration - 
Bolus insulin Meal time Insulin Basal Insulin 
Combinations 
c)  Antiplatelets : Yes/ No                           Duration : 
Cyclooxygenase inhibitors ADP receptor inhibitors Phosphodiesterase inhibitors 
Adenosine reuptake inhibitors Others -  
d)  Statins : Yes/ No                           Duration : 
Atorvastatin Simvastatin Rosuvastatin Others 
 
VII.  Examination –  
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Heart rate -  Blood pressure -              systolic/             diastolic 
Saturation  Room air Oxygen  (Fio2 ) BMI 
Respiratory rate Edema - Yes / No JVP – Elevated / Not elevated 
S3 - Yes / No Murmur - Yes / No Type - Rales -  Yes /  No 
GCS - Intubation – Yes /  No Duration - 
Wait circumference ( cm ) Hip circumference ( cm ) Waist / Hip ratio 
Killips class TIMI for STEMI TIMI for NSTEMI/ UA 
 
VIII. ECG :  
Anterior  wall Septum Anteroseptal 
Inferior wall Posterior wall Arrhythmia / Atrial fibrillation 
 
IX. Chest X – Ray :   
Pulmonary edema Pleural effusion Cardiomegaly Consolidation Others 
 
ECHO : RWMA Diastolic Dysfunction Ejection Fraction PAH 
 
X. Cardiac Enzymes :  
 Trop T CK- MB 
At admission   
After 6 hours   
Serial enzymes   
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XI. Investigations :  
Haemoglobin - HbA1c Serum Creatinine -   
Total Chol-   Triglycerides - HDL -   LDL - 
 
XII. Time of Hospitalization to time of appropriate intervention : 
XIII. Intervention : 
 
Discharge advice  
Antiplatelets -  Y/ N Clopidogrel Aspirin Others 
Statins -  Y/ N Atorvastatin Rosuvastatin Others 
Antianginal drug- Y/ N Sorbitrate GTN Others 
Antihypertensive -Y/N ACE inhibitors ARB Blockers Beta blockers 
Diuretics Others -  
Antidiabetic medications-Y/ N Oral - Yes / No  
Sulphonylureas Biguanides Alpha glucosidase inhibitors 
Parentral Therapeutic agents -  Yes / No 
Basal Insulin Bolus or Mealtime insulin Premixed Insulin 
Thrombolysis Streptokinase  Urokinase  rTPA Others  
Anticoagulation – Yes/No Heparin LMW Heparin Others- 
Inotropes – Yes/ No    
Treadmill- Yes/ No Stress test – Yes/No CAG- Yes/No 
PTCA-  Yes/ No CABG- Yes/ No Others - 
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XIV.  Follow up at Discharge, one month and 6 months : 
 Hospitalization  One Month Six Month 
Death Cardiac cause    
Death non Cardiac cause    
Reinfarction    
Cardiac Arrest    
Thromboembolic Phenomenon     
Blood pressure    
Antiplatelets -  Y/ N Clopidogrel Aspirin Others 
Statins -  Y/ N Atorvastatin Rosuvastatin Others 
Antianginal drug- Y/ N Sorbitrate GTN Others 
Antihypertensive -Y/N ACE inhibitors ARB Blockers Beta blockers 
Diuretics Others -  
Antidiabetic medications-Y/ N Oral - Yes / No  
Sulphonylureas Biguanides Alpha glucosidase inhibitors 
Parentral Therapeutic agents -  Yes / No 
Basal Insulin Bolus or Mealtime insulin Premixed Insulin 
Treadmill- Yes/ No Stress test – Yes/No CAG- Yes/No 
PTCA-  Yes/ No CABG- Yes/ No Others - 
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Blood glucose    
Exercise/ Daily walk      
Oil consumption    
 
11.3International Physical Activity Questionnaire 
 
             Think about all the vigorous activities that you did in the last 7 days.  Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe much 
harder than normal.  Think only about those physical activities that you did for at least 10 
minutes at a time. 
1. During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, aerobics, or fast bicycling?  
_____ days per week  
 
   No vigorous physical activities  Skip to question 3 
 
2. How much time did you usually spend doing vigorous physical activities on one of 
those days? 
_____ hours per day             _____ minutes per day           Don’t know/Not sure  
Think about all the moderate activities that you did in the last 7 days.  Moderate activities 
refer to activities that take moderate physical effort and make you breathe somewhat harder 
than normal.  Think only about those physical activities that you did for at least 10 minutes at 
a time. 
3. During the last 7 days, on how many days did you do moderate physical activities like 
carrying light loads, bicycling at a regular pace, or doubles tennis?  Do not include 
walking. 
_____ days per week      
 
   No moderate physical activities  Skip to question 5 
4. How much time did you usually spend doing moderate physical activities on one of 
those days? 
_____ hours per day              _____ minutes per day         Don’t know/Not sure  
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Think about the time you spent walking in the last 7 days.  This includes at work and at 
home, walking to travel from place to place, and any other walking that you have done solely 
for recreation, sport, exercise, or leisure. 
 
5. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time?  
_____ days per week 
  
   No walking     Skip to question 7 
6. How much time did you usually spend walking on one of those days? 
_____ hours per day              _____ minutes per day         Don’t know/Not sure  
The last question is about the time you spent sitting on weekdays during the last 7 days.  
Include time spent at work, at home, while doing course work and during leisure time.  This 
may include time spent sitting at a desk, visiting friends, reading, or sitting or lying down to 
watch television. 
 
7. During the last 7 days, how much time did you spend sitting on a week day? 
_____ hours per day          _____ minutes per day                      Don’t know/Not sure 
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11.4Patient information sheet 
11.4.1English 
Christian Medical College, Vellore 
Department of Medicine 
 
 
To study the Clinical characteristics, RIsk factors, long term Morbidity & Mortality of 
patients with Acute Coronary Syndrome (ACS) admitted in general medical wards CRIMM – 
ACS study 
 
Information sheet 
 
 
If you take part what will you have to do? 
If you agree to participate in this study, your base line data will be collected. You will 
also be administered TIMI scoring systems for Acute Coronary Syndrome (STEMI/ 
NSTEMI/UA) at admission.  
All the other treatments that you are already on will be continued and your regular 
treatment will not be changed during this study. You will be expected to come for 
routine reviews as advised by your physician. As per study guideline you are 
requested to review with us after one month and six months of discharge. Before 
starting the study, you will be asked questions about specific risk factors. Your vitals 
including temperature, oxygen saturation, heart rate, respiratory rate, blood pressure 
will be recorded at admission and at each visit. No additional procedures or blood 
tests will be conducted routinely for this study.  
If at any time you experience any problems, you will be expected to report this to the 
doctor. You will also be contacted by telephone or by post in case you do not follow 
up as advised.  
Can you withdraw from this study after it starts? 
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Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your 
usual treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you because of taking part in this study. 
Will you have to pay anything extra to take part in the study?  
You will not incur any extra charges for taking part in this study. We will also 
reimburse you and one person accompanying you the money that you spent on travel 
to come for review (please keep your bus or train tickets) for the visits that you make 
for this study. 
Any other treatment that you usually take will continue but the usual arrangements 
that you have with the hospital will decide how much you pay for this.  
What happens after the study is over? 
You may or may not benefit from the study that you are a part of. However, the 
conclusions drawn from this study will be useful to manage similar patients in future. 
 Will your personal details be kept confidential? 
The results of this study may be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your 
medical notes may be reviewed by people associated with the study, without your 
additional permission, should you decide to participate in this study.  
 
There will be approximately 200 participants enrolled for the study. The patient is 
expected to communicate the health condition to at most to his/ her knowledge.  
 
If you have any further questions, please ask  
Dr. Jaifrin Daniel 
Department of Medicine Unit 2 
Christian Medical College Hospital  
Vellore, Tamilnadu 
632004 
Tel: 0416 2282031 
Mobile No. 9789230877 
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email: jdaniel.m07@gmail.com 
     
11.4.2Tamil 
கிறித்துவ மருத்துவக் கல்லூரி 
ப ொதுமருத்துவத் துறை 
  
ப ொது மருதத்ுவத் துறை உட்பிரிவிை்கு வரும் மொரறட ்பு 
பிணியொளிகளில் - பிணி சொரந்்த அறிகுறிகள், அ ொய 
கொரணிகள், நநொய் ொதி ்பு மை்றும் இை ்பு முதலியவை்றை 
ஆரொய்தல் CRIMM – ACS ஆராய்சச்ி. 
  
தகவல் சீடட்ு 
  
இதில் பங்கேற்ே கேண்டுமெனில் நீங்ேள் என்ன மசய்ய 
கேண்டுெ்? 
  
நீங்கள் இதில் ங்நகை்க விரு ் ம் பதரிவித்தொல், முதலில் 
உங்கறள ் ை்றின தகவல் நசகரிக்க ் டும். பின்னர ்TIMI 
என ் டும் மொரறட ்பு கண்டறிதல் நகள்வி நகொர ்்பிலிருந்து 
நகள்விகள் நகடக் ் டும். 
  
  
பின்னர ்எல்லொ மருதத்ுவ சிகிசற்சகளும் அளிக்க ் டும்; 
நீங்கள் ஏை்கனநவ எடுத்துக்பகொண்டிருக்கும் சிகிசற்ச 
உட் ட. மருத்துவ கண்கொணி ்பிை்கொக டிஸ்சொரஜ்் 
பசய்ய ் ட்ட பின்னர,் ஒரு மொதம் கழிதத்ு ஒரு முறை, 6 
மொதங்களுக்கு ் பின்னர ்ஒரு முறை பதொடரந்்து 
மருதத்ுவமறனக்கு வர நவண்டியது இருக்கும். 
ஆரொய்சச்ியின் ஆரம் த்தில் பிணி சொரந்்த அ ொய 
கொரணிகள் ை்றி நகள்விகள் நகடக் ் டும். உங்களது உடல் 
உஷ்ணநிறல, நொடிதத்ுடி ்பு, இரத்த அழுத்தம், சுவொசிக்கும் 
நவகம் முதலியறவ ஒவ்பவொறு முறையும் கண்கொணிக்க ் 
 டும் நவறு எந்த இரத்த ரிநசொதறனநயொ, பசயல் 
முறைகநளொ கிறடயொது 
  
இந்த ஆரொய்சச்ி நறடப றும் கொலத்தில் மருத்துவ ரீதியில் 
என்ன நடந்தொலும் மருதத்ுவறர உடநன அணுக நவண்டும். 
ஒருநவறள நீங்கள் மருதத்ுவமறனக்கு வரொத ட்சத்தில் 
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பதொறல ்ந சியின் மூலநமொ அஞ்சல் மூலமொகநவொ 
பதொடரப்ுபகொள்ள ் டுவீரக்ள். 
  
இதில் பங்கேற்றப் பின்னர் இதிலிருந்து விலே முடியுொ? 
  
உங்களது ங்நகை்பு முை்றிலும் உங்களது சுய ஒ ்புதலின் 
ந ரில் தொன். எனநவ உங்களுக்கு விரு ் ம் இல்லொத 
 டச்த்தில் நீங்கள் எ ்ந ொது நவண்டுமொனொலும் விலகிக் 
பகொள்ளலொம். 
  
இந்த ஆராய்சச்ியினால் ஏகதனுெ் பாதிப்புேள் ேர ோய்ப்பு 
உள்ளதா? 
  
அதை்கு வொய் ்புகள் ஏதும் இல்றல; ொதுகொ ் ொனது தொன். 
  
  
இதில் ங்நகை் தை்கொக நீங்கள் ணம் பசலவு பசய்ய 
நவண்டுமொ? 
  
நீங்கள் வழக்கமொக பசலவுபசய்வறத விட ஏறனய 
பசலவுகள் ஏதும் கிறடயொது. உங்களுக்கும் உங்களுடன் 
வரும் ந ருக்கும், நீங்கள் ஒவ்பவொறு முறையும் மருதத்ுவ 
மறனக்கு வருறகயில் யனச ்சீடற்ட கொண்பிக்கும் 
 டச்த்தில், அந்த பசலவிை்கொன ணம் தர ் டும். நீங்கள் 
ப றும் மருதத்ுவத்திை்கொக பசலவு இதில் அடங்கொது. 
  
இந்த ஆரொய்சச்ி முடிந்த பின்னர ்என்ன நடக்கும்? 
  
உங்களுக்கு இந்த ஆரொய்சச்ியின் மூலம் லன் 
கிறடக்கலொம்; அல்லது கிறடக்கொமல் ந ொகலொம். ஆனொல் 
வருங்கொலத்தில் மொரறட ்பு வரு வரக்ளுக்கு அது 
பிரநயொஜனமொயிருக்கும். 
  
உங்கறள ் ை்றின தகவல் இரகசியம் கொக்க ் டுமொ? 
  
இந்த ஆய்வின் முடிவு புள்ளி விவரங்கள் மருதத்ுவ 
 த்திரிக்றககளில் திக்க ் டலொம். ஆனொல் அதில் 
உங்கறள ் ை்றிநயொ ப யர ்விவரங்கள் ஏதும் வரொது. 
ஆனொல் மருதத்ுவ கண்கொணி ் ொளரக்ள் உங்களது 
தகவல்கறள ் ொரக்்க முடியும். 
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இந்த ஆரொய்சச்ியில் சுமொர ்200 பிணியொளிகள் ங்நகை்கின்ைனர.் 
ஒவ்பவொறுவரும் அவரவருக்குத் பதரிந்த வறர விவரங்கறள 
பதரிவிக்க நவண்டும். 
  
 
 
நமை்கண்டவை்றில் ஏநதனும் சந்நதகங்கள் இருந்தொல் பதொடரப்ு 
பகொள்ளுங்கள்: 
  
டொக்டர ்பஜய்பிரின் டொனியல், 
ப ொதுமருத்துவத் துறை - 2, 
கிறித்துவ மருத்துவக் கல்லூரி மருதத்ுவமறன, 
நவலூர,் தமிழ் நொடு - 632004. 
 
பதொறல ்ந சி:  0416 2282031,  9789230877. 
மின்னஞ்சல்: : jdaniel.m07@gmail.com 
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11.5Consent form 
11.5.1English 
 
 STUDY - To study the Clinical characterstics, RIsk factors, long term Morbidity & Mortality 
of patients with Acute Coronary Syndrome (ACS) admitted in general medical wards – 
CRIMM- ACS study 
 
  
 
Study Title: 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions. [  ] 
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(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________Signature:  
 
Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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11.5.2Tamil 
 
இந்த ஆராய்சச்ியில் பங்கேற்பதற்ோன ஒப்புதல் படிேெ்: 
 
ப ொது மருதத்ுவத் துறை உட்பிரிவிை்கு வரும் மொரறட ்பு 
பிணியொளிகளில் - பிணி சொரந்்த அறிகுறிகள், அ ொய 
கொரணிகள், நநொய் ொதி ்பு மை்றும் இை ்பு முதலியவை்றை 
ஆரொய்தல் CRIMM – ACS ஆராய்சச்ி. 
  
 
ஆரொய்சச்ியின் தறல ்பு: 
  
ஆய்வு எண்: _________________ 
  
ந ரின் ப யர ்(துவக்க எழுத்துடன்): _________________ 
  
பிைந்த நததி (வயது): _________________ 
  
i. ------------------------- ஆம் நததியில், இந்த ஆய்விை்குரிய தகவல் 
சீடற்ட நொன் டிதத்ு புரிந்து பகொண்நடன்; நகள்விகள் நகடக் 
எனக்கு வொய் ்புகள் வழங்க ் ட்டது. 
  
ii. என்னுறடய ங்நகை்பு முை்றிலும் சுயவிரு ் த்தின் ந ரில் 
தொன்; எ ்ந ொது நவண்டுமொனொலும் எந்த 
கொரணத்திை்கொயினும் எந்த ஒரு ொதி ்பும் இல்லொமல் இந்த 
ஆய்விலிருந்து விலகிக் பகொள்ள எனக்கு உரிறம உண்டு 
என் றத அறிந்து பகொண்நடன். 
  
iii. பநறிமுறைகள் குழுவும் ஆரொய்சச்ி ஒருங்கிறன ்பு குழுவும் 
என்றன ் ை்றின தகவல்கறள எ ்ந ொது நவண்டுமொனொலும் 
 ொரக்்கலொம், இது நொன் இந்த ஆரொய்சச்ிறய விடட்ு 
விலகினொலும் ப ொருந்தும். இறத பிை்கொலத்தில் நறடப றும் 
ஆரொய்சச்ிகளிலும் யன் டுத்தலொம். 
  
iv. இந்த ஆரொய்சச்ியின் மூலம் கிறடக்கும் புள்ளி விவரங்கறள 
 யன் டுத்த நொன் தறடயொக இருக்க மொட்நடன்; அது 
ஆரொய்சச்ியின் யன் ொட்டிை்கு மடட்ும் இருக்கும் வறரக்கும். 
  
v. நமை்கண்ட ஆரொய்சச்ியில் நொன் ங்கு ப ை சம்மதம் 
பதரிவிக்கிநைன். 
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சட்ட ்பூரவமொக ஏை்றுக்பகொள்ள ் டும் ந ரின் றகபயொ ் ம்/ 
ப ருவிரல் நரறக 
  
நததி : _____/_____/______ 
  
  
ந ரின் ப யர:் _________________________________  
 
 
றகபயொ ் ம்: 
  
 
  
அல்லது 
  
  
  
உைவினர:் _________________ 
  
நததி : _____/_____/______ 
  
உைவினர ்ப யர:் _________________________________ 
  
  
ஆரொய்சச்ியொளரின் றகபயொ ் ம்: ________________________ 
  
நததி : _____/_____/______ 
  
ஆரொய்சச்ியொளரின் ப யர:் _________________________ 
  
  
சொட்சியின் றகபயொ ் ம்: ___________________________ 
  
நததி : _____/_____/_______ 
  
சொட்சியின் ப யர:் ______________________________ 
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11.6STROBE Checklist 
 
STROBE Statement—checklist of items that should be included in reports of observational 
studies 
 
 
Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods 
of selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and 
methods of case ascertainment and control selection. Give the rationale 
for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and number 
of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
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Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was 
addressed 
Case-control study—If applicable, explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary 
measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
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meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of 
Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at www.strobe-statement.org. 
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11.7 Modified kuppuswamy scale 2012 
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11.8Thesis data 
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